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Abstract 
‘ . I 
Yuehchukene (YCK) is a non-oxygen ^w-indole alkaloid isolated from the root of 
Murray pciniculata and was initially developed in pursuit of effective oral anti-fertility 
agents. It exerts potent anti-implantation activity in rats. 
Anti-estrogenic effects of yuehchukene (YCK) were observed in rat uterotrophic, 
mice vaginal smear and MCF-7 cell growth assays. Whereas yuehchukene per se was 
estrogenic in these bioassay models, the co-administration of yuehchukene and an optimal 
dose of 3,176-estradiol (estradiol) could attenuate the maximum estrogenic response due 
to estradiol alone. The anti-estrogenic effect of yuehchukene in rat uterine hypertrophy 
was corroborated by a parallel attenuation of ornithine decarboxylase activity in these 
tissues. 
Yuehchukene binds to rat, mice and MCF-7 cell estrogen receptor with a relative 
binding affinity of 1/150 to 1/300. This binding affinity was positively related to 
estrogenicity as determined by uterotrophic assay and MCF-7 cell growth. However this 
estrogenic effect did not correlate to the degree of competitive receptor binding by a 
weaker agonist. 
Indole-3-carbinol and methylbutadienylindole could induce ethoxyresorufin O-
deethylase and estradiol-2-hydroxylase in rat liver and MCF-7 cell. It is postulated that the 
'free' indole moiety of yuehchukene could possess similar induction activity. Thus 
yuehchukene may have a dual pharmacological function. While the intact molecule is a 
weak estrogen, the 'free' indole moiety in yuehchukene may induce an enhancement of 
estradiol-2-hydroxylase, thus terminating the biological activity of the endogenous 
/ . 
estrogen pool. There is obvious benefit in attenuating the estrogen level in post-
menopausal breast cancer patients without going directly to the use of tamoxifen or 
aromatase inhibitor, especially with this new type of molecular design among all known 
anti-estrogens. Yuehchukene may serve this purpose (Ng et al., 1994). In this context, the 
pharmacological evaluation of a hydroxylated yuehchukene analogue (TCP) and the 
estrogen attenuation effect of methylbutadienylindole acid-condensation products are 
underway. 
With structural resemblance to known protein kinase C (PKC) inhibitor, K252C, 
and confirmation of its in vitro PKC inhibition, the ^w-indole structure of YCK confers 
additional action mechanism which remains unclear whether it can contribute to the 
estrogen attenuation effect. It is worthwhile exploring this in light of the modulation of 
growth factors response in breast cancer tissues in the future. 
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1.1 Hormone and carcinogenesis 
Cancer is the major cause of death among women both in Hong Kong and other 
developed countries. In Hong Kong, cancer has claimed 8832 lives, i.e., 122 deaths per 
100,000 population according to the 1991 annual report from Department of Health. 
When compared to United States of America, their mortality rate per 100,000 population 
was 170 deaths in 1988. In fact, cancer is their leading cause of death in women between 
the ages of 35 and 74 (Boring, 1992). Table I showed the comparative study carried out 
in United States of America (Boring, 1992) over a 20-year period (1962-1982) in order to 
evaluate the progress against cancer. There is a 13% increase in the incidence of cancer 
and the absolute number of deaths increased 55.7%. The only progress is the five-year 
survival rate which increases from 38.5% to 40.1% during this 20-year period. Some 
scientists argued that this improvement in five-year survival rate is because it only 
reflects the fact that cancer can be detected earlier than in the past. Thus, it may appear 
misleading to conclude that cancer patients live somewhat longer than previously 
(Statland, 1992). 
Table I Progress against Cancer? 
Item 1962 1982 % change 
Incidence 
Crude rate/100,000 365 413 +13.0 
Age-adjusted rate 368 399 +8.5 
Mortality— 
No. of deaths 279,000 434,000 +55.7 
Crude rate/100,000 151 189 +25.1 
Age-adjusted rate 170 185 + 8.7 
Five-year survival rate 
Absolute survival rate 38.5 40.1 + 4.2 
Relative survival rate 46.8 49.2 + 5.1 
(Adapted from Statland, 1992) 
1 
It seems that the war against cancer has made little progress during these years. 
New therapeutic agents as well as new approaches in cancer management are earnestly 
required. Beside，the lack of an answer may stem from the lack of knowledge on the 
etiology as well as biology of various kind of tumours. One typical example is the 
hormone dependent cancer. 
Hormonal carcinogenesis can be viewed as the “induction of tumour (either 
benign or malignant) in endocrine organs and in their target tissues by endogenously 
produced or exogenously administered (synthetic or natural) hormones". According to 
published views (Li and Nandi, 1990)，this type of carcinogenesis shares the following 
characteristics: 
(1) Tissue specific; 
(2) Long induction period; 
(3) Prolonged hormonal exposure; 
(4) Cellular proliferation or hyperstimulation due to hormonal exposure; and 
(5) Potential activation of the parent hormone to active intermediate. 
It has long been regarded that hormones are implicated, either directly or 
indirectly in the induction and growth of various experimental tumours, including testis, 
ovary, prostate, vagina, uterus, mammary gland, liver, kidney, thyroid, anterior pituitary 
and lymphoid organs (Clifton, 1959; Bischoff, 1969; Lingerman, 1979; International 
Agency for Research on Cancer, 1979; Chandburg, 1981; Rivera, 1982; Hertz, 1957). 
However, the precise role as to how hormones affect cell transformations, whether in 
vitro or in vivo, remains obscure. This is not surprising due to the fact that hormonal 
modulation of cellular processes such as growth, differentiation and metabolism are 
already complex events, and many aspects are poorly understood. One current 
2 
‘ . ‘ • ‘ 
hypothesis states that hormone is probably not carcinogenic itself but increases the 
susceptibility of host or target tissues when embracing other carcinogenic factors, like 
virus, environmental factor, toxin, chemicals or ionising radiation (Li and Nandi, 1991). 
Another hypothesis states that hormones play a dual role in carcinogenesis. They are a 
prerequisite for the initial transformation as well as causing an increase of susceptibility 
(Nandi, 1978). 
1.2 Estrogen and carcinogenesis 
1.2.1 Carcinogenesis and endogenous sex hormone status 
It has long been thought that endogenous hormone status is related in some way 
to the etiology of a number of hormone-dependent carcinogenesis. This is based on the 
results of animal experiments, responsiveness of cancer patients to hormonal 
manipulation as well as the result of surgical removal of ovarian function in certain 
tumours. However, excepting the endometrial cancer (Brinton, 1984)，there is little 
success in identifying the specific hormonal factors that might be responsible for these 
tumours. 
1.2.2 Etiology of breast cancer 
1.2.2.1 Epidemiology 
Speculation of hormonal cause in some human carcinogenesis has long been 
raised and a number of these have been shown to respond to hormonal manipulation. 
However, the precise role of hormone in the carcinogenesis as well as the promotion of 
cancer growth remain unclear. For example, in the case of breast cancer, it is widely 
appreciated that cumulative estrogen exposure predisposes the risk of developing breast 
cancer (Henderson et al., 1988). However, high dose (pharmacological dose; e.g., 5 mg 
orally administered, 3 times a day) of estrogen (Kennedy, 1969; 1965) and progesterone 
3 
(Aisner et al., 1987) can induce regression qn some human breast cancers. The 
mechanism of such paradoxical response is still a mystery. 
Breast cancer is a major disease of women in western hemisphere. This represents 
30% of all types of cancer in women. The medium age of developing this cancer is in the 
late fifth decade. Of these, about 22% of deaths are due to lung cancer, 19% to breast 
cancer, and 12% to colon and rectal cancer. The most disturbing fact is that the 
incidence of breast cancer has not decreased in the past 30 years. 
According to the annual report of the Department of Health, breast cancer was the 
second major cause of death among all women died of cancer in Hong Kong. However, 
the mortality rate per 100,000 population is increasing from 8 to 11.8 during last decade 
(from 1982 to 1991). The number of patients died of breast cancer increased from 202 
in 1982 to 333 female subjects in 1991. Table II compared the percentage of cancer 
death for women in the United States of America (1992; Statland, 1992) and Hong Kong 
(1991，Annual Report 1991/92, Department of Health, Hong Kong). While it is 
agreeable to note that the percentage death due to breast cancer in Hong Kong is only 
half of that in the United States of America, this difference can probably be attributed to 
a difference in dietary factors between western and eastern diets. However, more 
alarming is the fact that there is a 50% increase of death due to breast cancer over the last 
10 years (from 1983 to 1992) in Hong Kong. This might be due to the fact that people in 




Table II Percentage of cancer death for women in Hong Kong and U.S.A. 
Disease group U.S.A.(1992)* Hong Kong (1991)** 
Lung cancer 22 26 
Breast cancer 19 10 
Colon cancer 12 9 
* data from Statland, 1992 
** data from Annua丨 Report 1991/92, Department of Health, Hong Kong, 1991 
The epidemiology of breast cancer in women has been studied extensively. 
While many controversies are still unsolved, some important risk factors are widely 
accepted (MacMahon et al., 1973; Miller, 1973; Kelsey, 1979; Vessey, 1985). These 
include 1) first full-term pregnancy happens after 30 years old; 2) nulliparity; 3) sex, age, 
height, weight, early menarche or late menopause; 4) dietary factors; 5) country of origin; 
and 6) family history of breast cancer. In addition, certain exogenous factors, such as 
hormone exposure, either the estrogenic component in birth control pill or the estrogenic 
contaminant in the environment, may also be of great importance. Many of these factors 
are inter-dependent and it seems that most of them are associated with endocrine factors. 
1.2.2.2 Hormonal factors 
Ovariectomy before the age of 35 has been found to be associated with a lower 
incidence of breast cancer. In 1896, Beatson (1896) reported dramatic improvement 
following castration in three patients with breast cancer. The hormones, estrogen and 
progesterone, have both been identified to be important in the regulation of the female 
reproductive function as well as the development of breast tissue. Estrogen is believed to 
be critical for the growth of ductal epithelium of breast and progesterone is required for 
the development of acini. The normal function of the mammary gland also requires 
growth hormone, prolactin and other growth factors. However, except for the 
5 
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endometrium cancer, which had been shown to have a causal relationship between the 
risk of cancer development and estrogen, no hard evidence has been obtained to associate 
estrogen and the development of breast cancer, although the current view that length of 
exposure to estrogen (either from exogenous or endogenous source) is believed to be 
responsible for the development of breast cancer. Nevertheless, it is fair to say that 
estrogen plays an essential role in the etiology of the development of breast cancer. Just 
like all the other hormones, stringent regulation within the whole body is required. 
Prolonged and severe derangements in normal homeostasis and regulatory machinery 
may finally precipitate the stage of carcinogenesis. 
As mentioned in the epidemiological study of breast cancer, those endocrine-
related factors, such as first full-term pregnancy age, early menarche or late menopause, 
nulliparity, appear to be related to the extent of cumulative estrogen exposure. Estrogen 
was found to be able to increase directly the incidence of breast cancer (Henderson et al., 
1988). Exogenous estrone, estradiol and, under certain circumstance, estriol, can 
increase the incidence of mammary tumours in mice and rats. They also increase the 
tumour size and decrease the time required to induce mammary tumour after 
administration of chemical carcinogen, DMBA (dimethylbenzanthracine) (Dao, 1981). 
Attempts to quantify and confirm the role of estrogen in human breast cancer 
development have been hampered, to a certain extent, by the technical difficulties for 
accurate concurrent measurements of steroid hormones in human blood, urine and fecal 
specimens. Based on these measurements, it is proposed that the postmenopausal breast 
cancer patients had significantly higher levels of total estradiol and free estradiol and 
significantly less steroid hormone binding globulin (SHBG) (Moore, 1982) than controls. 
In one study, it was found that the level of free estradiol in patients was nearly 4 times as 
that of the control (Moore, 1982). However, more data are needed to establish an 
unequivocal and positive relationship between estrogen level and breast cancer. 
6 
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Another source of estrogen comes from oral contraceptive. By 1978，World 
Health Organization (WHO) estimated that around 80 million women throughout the 
world had been exposed to these drugs. Hence, it would be a valuable venue to 
substantiate the critical role of estrogen in the pathogenesis of breast cancer. Although 
large amount of studies have been documented, it remains a major subject of controversy 
(Editorial of Lancet, 1985; McPherson，et al.，1983; Stadel, 1986; Prentice and Thomas, 
1987). For those showing a positive correlation, studies showed that long duration of 
oral contraceptive use (6 or more years) confers at least 50% increase in breast cancer 
risk. This increase of risk was associated with the use of contraceptive during the 
perimenopausal period (women at their fourth and early fifty decade) or women at a 
young age and before having their first child. Both cases represent the risk due to an 
extension of estrogen exposure. In the former case, the increased risk is that oral 
, ‘ 
contraceptive use masks the onset of menopause by producing a hormonal state 
approximating that of normal menstruation. For the latter one, the postmenarcheal 
period is characterised by frequent anovular menstrual cycles, exposure to oral 
contraceptives may provide higher levels of estrogens than would have occurred 
naturally. K also suggested that the timings for both menarche and first full-term 
pregnancy are critical risk factors for breast cancer. 
As it was clearly demonstrated by these results, lowering the endogenous estrogen 
level in target tissues should have beneficiary effects on breast cancer management, 
especially in those pre-menopausal patients. In fact, it forms the basis of the endocrine or 
hormonal therapy in breast cancer management. It leads to the emergence of anti-
estrogen, such as tamoxifen，which was originally designed for an anti-fertility agent, and 
other therapeutic means as mentioned later in more details. 
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1.2.2.3 Genetic predisposition 
Genetic factor (Anderson, 1977; King et al.’ 1980) might also be involved in a 
small percentage of breast cancer patients, as evidenced by the existence of high-risk 
families with a history of breast cancer. Recently, a gene called brcal (Ford et al., 1994) 
has been identified and it is suggested to provoke some breast cancer. However, the gene 
product as well as the action mechanism remain unclear. 
1.2.2.4 Influence of diet 
Diet is also suspected to play a role in breast cancer development. The major 
evidence, though inconclusive, comes mainly from studies that examined the rates of 
cancer on people who emigrated (Kelsey, 1979; Waterhouse et al., 1976; Pike et al” 
1981; Lee et al., 1991). For example, the number of breast cancer patients in Japan is 4 
times lower than that in the United States of America. When Japanese women move to 
the United States of America, they or their daughters eventually have the rate of 
occurrence just as those in North America. Hence, Pike and his colleagues (1981) raised 
the hypothesis that altered dietary habits clearly led to increased height and weight and 
early onset of menstruation. This could result in increased risk of breast cancer. Some 
attributed this to only dietary fat, however. Some suspected that probably certain 
micronutrient of the diet, or even the contaminant(s) of diet, e.g., zearalenone could also 
. I 
contribute to carcinogenesis. This is probably effectuated through intervention of 
endogenous hormonal factors, for instance, high fat diet provides more cholesterol and 
thus hormone biosynthesis in the adipocytes in obese women. 
Many other causative factors have also been proposed to be involved. Those 
mentioned above are probably the most important and relevant to our discussion. For 
prophylactic purpose, it may be fair to suggest that tightly regulated estrogen level, high 
intake of fibre in a low fat diet, lowering the endogenous estrogen level by avoiding 
8 
exposure to xenoestrogen seems to be beneficial. As far as economic consideration is 
concerned, a preventive approach may be better than a therapeutic one. Indeed, NCI 
estimates that approximately one-third of cancers could be brought on by diet or personal 
behaviour such as smoking (Michnovicz et al., 1989)! However, it is not easy to identify 
the proximal factors which can be useful in prevention. A better understanding about the 
course of carcinogenesis needs to be established before this strategy can be applied. 
As mentioned above, a more satisfactory approach to solve the cancer problem 
would be to prevent people from ever developing cancer. According to NCFs Cancer 
Cause and Prevention Group, "Nutritional science is coming of age ... "(Gori, 1981). 
Some epidemiologists suggest that most cancer, 65%-70%, are caused by factors 
associated with lifestyle, in particular the use of tobacco, alcohol and diet (Statland, 
1992)，of which about 30% are directly or indirectly linked to nutrition. 
The nutrition-cancer link has been supported by epidemiological studies (Cohen, 
1987). It has been reported that high-fat diets lead to an increased secretion of prolactin 
and prostaglandins (Schindler et al., 1972). Also, the high fat diet facilitates an increase 
in estrogen production as it is also synthesised peripherally in the fat cells (Schindler et 
al., 1972). Barbosa et al. (1990) compared serum estradiol level for vegetarians and non-
vegetarians. As shown in Table HI, significantly lower value of serum estradiol 
concentration is observed in the vegetarian group. It is also proposed that a high fat diet 
is associated with an early menarche as well as a late menopause. This prolongs the 
period of time in which women experienced high level of estrogen. Besides, high fat diet 
also prolongs a higher level of estrogen in postmenopausal women, through peripheral 
conversion. 
9 
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Table III Vegetarian vs. Nonvegetarian Elderly Women ； 
Item I Vegetarian Nonvegetarian 
Age, years 75.5 71.5 
, I 
Body fat, % 27.8 32.8 
Dietary fibre in diet, g/day 24 13 
Saturated fatty acids in diet, g/day 10 17 
Cholesterol in diet, mg/day 72 181 
Serum estradiol. pmol/L 13.1 23.8 
(Adapted from Barbosa, 1990) 
Adlercreutz (1981) announced that "particularly in women, who have a much 
higher incidence of hormone-dependent cancers than do men, diet has been suggested as 
the main single determinant in the etiology of these cancers.". His thorough study 
revealed that a western diet with high fat and protein intake, low intake of fibre and 
whole grain products is apparently related to high plasma sex hormone levels, low steroid 
hormone binding globulin (SHBG), high level of sex hormone excretion, and low urinary 
phytoestrogen and lignan excretion. 
This nutrition-cancer link has also been studied in animal system. In the typical 
rodent experiment, animals are exposed to a carcinogen such as DMBA acting as an 
initiator of carcinogenesis. Then various types of diets are fed to the animal (Carroll and 
Khor, 1971). According to these experiments, it is speculated that dietary fat may be a 
promoter in the development of cancer (Roger, 1983). The most obvious dietary 
components identified to be preventive from ever developing cancer are dietary fiber, 
vitamins E, A, C, B-carotene, selenium, indole-3-carbinol and protease inhibitors. 
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Micronutrients in food can contribute to either prevention or initiation of 
carcinogens. Cancer-protective factors from food can help the protection against cancer 
initiation, promotion or conversion. They may either act on one of these stages or on 
multiple stages. They can be found in vegetables, fruits, and commonly used herbs 
(Dragsted et al., 1993). As far as chemical structure is concerned, it can be classified to 
include polyphenols, thiols, carotenoids and retinols, carbohydrates, trace metal, 
terpenes, tocopherols, and degradation products of glucosinolates (indoles, dithiolthiols, 
isothiocynante). Although most action mechanisms of these factors remain obscure, 
some have been attributed to their scavenging effect or anti-oxidant effect on activated 
mutagens and carcinogens. For example, the carotenoid quenches the singlet oxygen and 
it also acts as an antioxidant, it inhibits the initiation as well as the promotion of 
carinogenesis (Cohen, 1987). 
Some of these entities included phytoestrogen, indole compounds and 
dithiothioles as represented by glucosinolate in cruciferous vegetables, dietary fibre and ‘ 
carotenoid. In light of the current understanding in hormone promoted carcinogenesis, 
the mechanisms concerned probably involve estrogen biotransformation or metabolism, 
either through modulation of entero-hepatic reabsorption or bio-inactivation of 
endogenous estrogen pool. 
• ‘ . 
、 
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Of particular interest are the phytoestrogens (including lignans, e.g., 
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Structures of some phytoestrogens (equol and enterolactone) and indole-3-carbinol 
• I 
Phytoestrogens, for example, equol, are compounds derived from many plants 
and vegetables. It possesses weak estrogenic activity and competes for estrogen 
receptors in target tissues, including uterus and human breast cancer cells (Shutt and 
Cox, 1972). It can exert mitogenic action in the MCF-7 human breast cancer cell culture 
(Martin et al., 1978; Welshons et al., 1987) in vitro. The dietary phytoestrogens, equol, 
are mainly produced by soybean products which contain equol precursor. Soy is a 
significant part of traditional Chinese and Japanese diet. However, despite its intrinsic 
estrogenicity, it has been argued that, by competing with the more potent estrogenic 
estradiol for the same binding sites, it may help to attenuate estradiol action and hence 
exerting an anti-estrogenic action (Martin, et al., 1978; Folman and Pope, 1969). In vitro 
experimental results are controversial and demonstrate mainly estrogen agonistic effect 
12 
(Welshons et al” 1987; Martin et al., 1978). It is the epidemiological observations 
leading to the hypothesis that phystoestrogens have a protective role in breast cancer. For 
example, the traditional Japanese diet is not only low in fat, but also includes 
considerable amounts of soy products. High urinary excretions of phytoestrogens, 
including equol, was observed (Adlercreutz et al., 1988). Furthermore, a study from 
Singapore indicated that breast cancer risk was inversely related to the consumption of 
soya-containing foods (Lee et al., 1991). In vivo inhibitory effects of soybean on 
DMBA-induced mammary tumour of rats have also been demonstrated (Baggott et al., 
1990). 
In the case of dietary fibre, Schultz and Howie (1986) found that unconjugated 
estrogens readily bind to some types of fibre and that the water-insoluble fibres present in 
high concentrations in the food typically consumed by vegetarians have a particular high 
capacity for binding estradiol and estrone (Whitten and Schultz, 1988). In addition, 
mounting evidences obtained from epidemiological study demonstrate that a high-fibre, 
low-fat diet was associated with high fecal estrogen excretion but low urinary estrogen 
levels. Comparison between Chinese women recruited from rural location and British 
women (Key et al., 1990)，both including pre- and postmenopausal women, showed 
similar result as those comparing Japanese and American women. The low-risk Chinese 
women had lower circulating estradiol levels than the high-risk British women. The 
difference was evident regardless of menopausal status. 
Lignan metabolites are members of a second class of compounds with mixed 
estrogen/antiestrogen biological properties. They are formed from intestinal bacterial 
action on the plant-derived precursors. Epidemiological observation found that increased 
intake of dietary fibre has a positive correlation with high level of lignan in urine 
(Adlercreutz et al., 1981; 1982). The principal lignan metabolites excreted in human 
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urine are enterolactone and enterodiol. They have a 2，3-dibenzylbutane backbone and 
C-3, C-17 hydroxyl groups similar to that of diethylstibestrol, a synthetic non-steroidal 
estrogen. Therefore, both can compete with rat uterine estrogen receptor albeit relatively 
weakly and exhibit estrogenic activity (Adlercreutz et al., 1986). An interesting property 
of enterolactone is its ability to inhibit placental aromatase, the enzyme also found in 
adipocytes is responsible for the conversion of androgen to estrogen, which is the major 
source of estrogen in postmenopausal women. Since aromatase inhibitors play an 
important role in the endocrine therapy (describe in section 1.2.3 with more detail) of 
breast cancer, speculated mechanisms for the proposed protective effect of enterolactone 
on breast cancer includes attenuation of both estrogen biosynthesis (aromatase inhibition) 
and its bioactivity (competing for estrogen receptor). 
Adlercreutz et al. (1986; 1982) observed that enterolactone and enterodiol 
excretion were lower in postmenopausal breast cancer patients than in healthy vegetarian 
women with similar menopausal status. 
14 
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The indole compounds from a group of common vegetables of the cruciferae 
family, which include cabbage, broccoli, brussel sprouts and cauliflower, have received 
much attention in recent years due to their cancer-preventive action. 
•ndole-3-Carbino丨（I3C) lndolo[3,2-b]carbazole 
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Structures of some examples of indole-3-cabinol acid condensation products 
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It was first identified to be responsible for inhibiting the polycyclic aromatic 
hydrocarbon-induced neoplasia in laboratory animals (Wattenberg and Loub, 1978). It is 
now well accepted that indole-3-carbinol (I3C) and other compounds present in 
cruciferous vegetables have anti-carcinogenic properties. Increased consumption of these 
vegetables seems to be associated with reduced tumour incidence in human (Young and 
Wolf, 1988; Graham et al., 1972) and experimental animals (Wattenberg, 1978; 
Stoewsand et al” 1988; Bradlow et al., 1991a). I3C also acts as antioxidant and 
intervenes the carcinogenesis/toxicology process by means of free radical scavenging as 
well as electrophilic mechanism (Shertzer et al., 1988; Fong et al., 1990). However, its 
action may be indirect since it can readily polymerise under mild acid environment such 
as that found inside the stomach. Analysis on extract isolated from stomach of the 
animal that has consumed I3C shortly has confirmed that I3C polymerised into a number 
of polymeric indole compounds, such as 3,3，-diindolylmethane (DIM) and 5,6,11,12,17, 
18,-hexahydrocyclonona[ 1,2-b:4,5-b' :7,8-b"]tri-indole (CT), and many others. 
It is proposed that the induction of cytochrome mono-oxygenase of CYP450 
family is associated with the preventive function of I3C, including the preventive effect 
on hormone-dependent breast cancer. Jellinck et al., (1991; 1992) showed that oral 
administration of I3C to female mice and rats increased the ability of their liver 
microsomes to convert estradiol into its catechol derivatives by estrogen 2-hydroxylase. 
I3C can increase both cytochrome P450 mono-oxygenase level in the rat liver and aryl 
hydrocarbon hydroxylase activity. It can protect the covalent binding of carcinogen to 
DNA and protein. It prevents the free-radical mediated hepatotoxicity and lipid 
peroxidation. Its modulation on certain P450 enzymes leads to the perturbation of 
endogenous sterdid hormone metabolism. This may be of paramount importance in 
endometrial and breast cancers, which appear to be related to the endogenous estrogen 
level. In fact, this perturbation results in favouring the 2-hydroxylation pathway of 
16 
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estradiol rather than the 16a-hydroxylation one. The significance of this competing 
pathway (please refer to the page overleaf) lies in the observation that alternation of the 
2- and 16a-hydroxylation ratio in favour of the latter has been shown to link with 
mammary tumour formation (Fishman et al., 1984; Bradlow et al., 1991b). It is found 
that the 16a-hydroxyestrone, unlike estrone or estradiol, can form a stable adduct with 
protein (Yu and Fishman, 1985; Miyairi et al., 1991), including the nuclear estrogen 
receptor, whereas the 2-hydroxyestrone has no estrogenic activity. Positive correlation 
between the increase of estrogen 16a-hydroxylase activity and higher risk of breast and 
endometrium cancer have also been established in animal models (Osborne et al” 1988; 
Bradlow et al., 1985; 1991b) as well as in women (Fishman et al., 1984). Besides, recent 
experimental data suggested that some of the polymeric indole compounds from I3C can 
bind to hepatic aryl hydrocarbon (Ah) receptor (Jellinck et al., 1993) and it was shown by 
Western blot experiment that dietary indoles induced specific cytochrome P450 enzymes 
in rat liver (Jellinck et al., 1993). They proposed that these indoles induced specific 
cytochrome P450 enzymes in liver through a mechanism involving the Ah receptor. 
These induced mono-oxygenases, in turn, increase the synthesis of catecho-estrogens in 
the competing pathways of 2- and 16a-hydroxylation. Tiwari et al. (1994) have reported 
that indole-3-carbinol, when administered at high concentration (larger than 5 |jM), could 
suppress the growth of both the estrogen receptor positive cell line, MCF-7, and the 
estrogen receptor negative cell line, MDA-MB-231 although the former was more 
sensitive to this treatment for obscure reasons. 
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1.2.3 Hormonal Therapy 
Hormonal therapy for breast cancer began with the observation by Beatson (1896) 
in 1896 that bilateral ovariectomy caused tumour regression in selected premenopausal 
patients. Later, Huggins and Bergenstal (1952) introduced the adrenalectomy as a form 
of hormone ablative for postmenopausal women whose estrogen was mainly converted 
from androgen in the peripherial tissues by the action of aromatase as illustrated in 
previous page. Besides, surgical intervention by hypophysectomy and hormonal additive 
therapies such as the additional use of androgens, estrogens, progestins and 
glucocorticoids were added to the hormonal therapy. 
However，only about one-third of patients yielded tumour regression with any of 
these hormonal therapies. In the 1960，s to 1970，s，clinicians favoured the use of 
cytotoxic chemotherapies. Multiple drug combination protocols had been developed and 
gained wide acceptance among clinicians. The turning point began in mid-1970，s，when 
the quantitative measurement of hormonal receptor was introduced. Hence, better 
identification and selection of patients carrying hormonal responsive tumour for 
hormonal therapy became possible. A large body of experimental and clinical treatment 
protocol emerged and were accumulated for the choice of clinicians. These various 
protocols combined radiotherapy, chemotherapy as well as endocrine therapy with the 
guidance of prognosis factors such as estrogen receptor and progesterone receptor. 
1.2.3.1 — Anti-estrogen 
Steroid hormone antagonists are compounds that compete with steroid hormone 
receptor but fails to initiate the normal responses and therefore inhibit the action of the 
hormone. Their main applications are the control of fertility and treatment of hormone-
dependent cancer. For treatment of breast cancer, the most widely clinically used anti-
estrogen is tamoxifen which belongs to the triphenylethylene class of anti-estrogen with 2 
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Tamoxifen (TAM) 丨C丨 164,384 
/ OH 
n X Y J A /Me 
Structure of anti-estrogen: tamoxifen and 丨C1164384 
rings corresponding to the A and D rings of estradiol. The trans form of tamoxifen is an 
antagonist while the cis form is a weak agonist. Tamoxifen is converted, mainly in the 
liver, to 4-hydroxy-tamoxifen, and this conversion increases its affinity for estrogen 
receptor by approximately 100 fold and consequently increases its potency (Jordan et al., 
1977). Although it has become an effective drug for the treatment of hormone-dependent 
breast cancer, it was realised that it was actually a partial agonist (Jordan and Murphy, 
1990). In other words, it can inhibit the action of estrogen while it exhibits certain 
estrogenicity by itself. 
The mechanism of action of tamoxifen involves binding to estrogen receptor and 
subsequent blockade of expression of estrogen functions induced by endogenous 
estrogen. Weak estrogen agonistic actions are observed in certain tissues, such as 
endometrium lining, especially in a milieu of low endogenous estrogen levels. 
Additional effects on protein kinase C, calmodulin (action on these two aspects will be 
described in section 1.6) cytochrome P-450, muscarinic, dopamine, and histamine 
receptors have also been observed in vitro. 
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Extensive studies since the mid-1970's have valued the benefits of endocrine 
therapy as an adjunct to surgical therapy like mastectomy. The rationale was to control 
or eliminate micrometastases before the onset of tumour recurrence. This type of therapy 
is known as adjuvant therapy. Tamoxifen, used as an endocrine therapeutic means, was 
chosen for the majority of these studies (Henderson, 1987; Lippman, 1986). In 1985, a 
Consensus Development Conference sponsored by National Institute of Health (NIH) 
took place and the conclusion about the adjuvant therapy was reached. It recommended 
the use of tamoxifen for estrogen receptor positive, postmenopausal patients but not for 
estrogen receptor negative or premenopausal women. In the majority of those 
premenopausal women, tamoxifen is unable to achieve a full anti-estrogenic effect at 
least at the level of uterus. This may result from the fact that tamoxifen administration in 
premenopausal women markedly stimulates ovarian estrogen production. Thus, it is 
possible that the resulting high serum estrogen level may offset the anti-estrogenic effect 
of the drug through direct competition at the estrogen receptor level. The mechanism 
underlying this observation remains unknown. 
Tamoxifen is a particularly useful drug because it has relatively few severe side 
effects. The most common side effects include nausea and worsening of hot flashes 
which occur in approximately 10% of patients. It does not cause osteoporosis, which is a 
potential risk as the result of estrogen deprivation. Tamoxifen also has the beneficial 
side effect of reducing blood cholesterol levels, which may cause reduced mortality from 
coronary heart disease (Nayfield et al., 1991). Recently, it is suspected that prolonged 
use of tamoxifen cause liver cancer and endometrium cancer. It acts as a strong agonist 
in endometrial cells, probably by means of a novel receptor (Butta et al.,1992). The 
molecular basis of cell specificity remains unknown. Despite the efficacy of tamoxifen 
treatment, most patients eventually develop drug resistance. The basis for this resistance 
is unknown but is unlikely to be simply due to a loss of receptor. It may result from 
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mutations in the estrogen receptor (Fuqua et al., 1991) or alterations in the metabolism of 
tamoxifen (Osborne et al., 1991, 1992). 
In order to have an anti-estrogen devoid of any estrogenicity, 4-hydroxylated 
tamoxifen and the ‘pure’ anti-estrogen, such as the ICM64,384 (Wakeling and Bowler, 
1987) have been developed and undergone clinical trial. 
1.2.3.2 Progestins 
Progestin therapy has proved useful in the treatment of advanced breast cancer. 
The precise mechanisms of its antitumour action are unclear. There are several 
possibilities. Firstly, it may exert a direct antiproliferative effect (Horwitz and 
Freidenberg, 1985; Allegra and Kiefer, 1985) and eliminate the stimulatory effect of 
estradiol on growth (Allegra and Kiefer, 1985). It may exert this effect directly by 
increasing the 176-hydroxy-steroid-dehydrogenase (Liu and Tseng, 1979) and thus 
enhancing the conversion of estradiol to estrone, an estrogen with lower potency. This 
effect is probably mediated through the progesterone receptor (Fournier et al., 1985). 
Furthermore, progestin is regarded as a physiological modulator of estrogen action as 
mentioned in section 1.4，it can suppress the estrogen receptor concentration (Clark and 
Peck, 1979). Due to its binding affinity to androgen and glucocorticoid receptors in 
human breast cancer tissues (Teulings et al., 1980)，some other alternative mechanisms 
may be responsible. 
It has been observed that high doses (larger than 500 mg/day by injection or 1000 
mg/day orally) of progestin is required to have effective anti-tumour action (Klaassen et 
al, 1976). Several randomised clinical trials have shown that megestrol acetate 
(progestin) and tamoxifen have similar anti-tumour action in postmenopausal women 
with advanced breast cancer. 
21 
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Toxicity of progestin therapy was found to be dose-dependent and was almost 
exclusively observed in patients treated with high dose. Most side effects come from the 
glucocorticoid-Iike activity of high dose progestin. These side effects include 
hypertension, hyperglycemia, edema, congestive heart failure, diarrhea, and 
hypercalcemia (Aisner et al., 1987; Otteman and Long, 1984; Kaufman et al., 1964). 
1.2.3.3 Aromatase inhibitor 
The aromatase enzyme is the rate limiting step in estrogen biosynthesis that 
converts androstenedione to estrone (Simpson et al., 1989). Aromatase catalyses a 
complex reaction with three separate steroid hydroxylations. Each involves NADPH as 
cofactor and an aromatase-specific cytochrome P-450 to insert molecular oxygen into the 
steroid structure. In premenopausal women, the most important site of aromatase action 
is the ovary. In the granulosa cell compartment, FSH stimulates the activity of aromatase 
by increasing the amount of aromatase mRNA and the number of enzyme molecules. 
Because of the complexity of regulation in the ovary, pharmacological blockade of 
ovarian aromatase has been difficult in patients. Inhibition of estrogen biosynthesis 
reduces the inhibitory action of estradiol on LH and FSH secretion. The reflex rise in 
FSH stimulates production of new aromatase enzyme, and the LH increase results in 
enhanced ovarian steroidogenesis in the theca compartment. These two effects tend to 
counteract the inhibitory action of aromatase blocking drugs on the ovary. In 
postmenopausal women, the granulosa cell compartment of the ovary is lost and the 
aromatase activity fall precipitously (Siiteri and MacDonald, 1973). Estrogen synthesis 
takes place nearly exclusively in extraglandular tissues in such individuals. 
Extraglandular aromatase is present predominantly in fat, liver and muscle. 
Androstenedione serves as the predominant substrate for aromatase. The adrenal directly 
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secretes androstenedione which enters these tissues for aromatisation to estrone. A small 
fraction of androstenedione is secreted by the ovaries as well. 
Through the androstenedione to estrone pathway, obese postmenopausal women 
produce approximately 50-100 |ig of estrone per day (Kirschner et al., 1982). A 
substantial fraction of estrone is converted to estradiol in the circulation (10-20 pg/ml). 
This level of estradiol should not be sufficient to occupy a fraction of tumour estrogen 
receptor to give meaningful biological response (Bradlow, 1982). However, some 
authors argue that the levels of estradiol in tumour tissue are one order of magnitude 
higher than in plasma and, thus, it may be sufficient for an important level of receptor 
occupancy (Edery et al., 1981; Fishman et al., 1977). However, the mechanisms 
responsible for the maintenance of high tissue estradiol concentrations are not clear yet. 
It possibly involves local production through aromatase or sulphatase (Santen et al” 
1984) in the tumour itself or the surrounding tissues. The absolute level of aromatase in 
normal tissues are relatively low, ranging from 5-100 pg/g tissue/hour when compared to 
human placenta. Aromatase, however, was found to be localised in specific cell types 
such as adipocytes, stromal cells of uterine, or certain epithelial tumour cell (0，Neill and 
Miller, 1987). 
, ‘ 
The biological significance of tumour aromatase rests in the concept that 
aromatase inhibitors would block estradiol synthesis directly at the site of the tumour. 
The first aromatase inhibitor is the aminoglutethimide (AG), which was initially 
recognised as an inhibitor of cytochrome P-450-mediated steroid hydroxylations and 
. I 
particularly of those involving the cholesterol side-chain cleavage enzyme. The initial 
clinical use of AG was to produce a ‘medical adrenalectomy，. Replacement of 
glucocorticoid was needed to compensate for the inhibition of Cortisol biosynthesis. The 
combined use of AG and hydrocortisone inhibited plasma and urinary estradiol to levels 
23 
comparable to those observed after surgical adrenalectomy (Santen et al., 1981) or 
hypophysectomy in patients with breast cancer. Detail investigations of the endocrine 
effects of AG plus hydrocortisone showed that it involved several mechanistic pathways 
(Table. IV). Clinical responses of the administration of AG plus glucocorticoid in 
women with breast cancer revealed similar result as those received anti-estrogen therapy. 
About one-third of women experience either complete or partial tumour regression of 
which 54% with estrogen receptor positive tumours responded with objective regression 
(Petru and Schmahl，1987). The major side effects include drug rash, fever, and lethargy 
with standard dose of AG (1000 mg daily). The severity of side effects, particular when 
compared to tamoxifen administration, has led to the attempts to reduce AG dosage as 
well as the development of a new generation of aromatase inhibitors, such as CGS 
16949A and 4-hydroxyandrostenedione. 
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1.2.3.4 GnRH analogue therapy 
The antiestrogen, tamoxifen, is effective in premenopausal women with advanced 
breast cancer but does not provide complete antagonism to the effects of ovarian 
estrogens. Ovariectomy, as an alternative to tamoxifen, is destructive and irreversible. 
Thus, any means of completely suppressing estrogen production, such as aromatase 
inhibition or continuous infusion of GnRH analogues would be desirable in order to 
reach a state of ‘medical castration，which can enhance the efficacy of anti-estrogen 
therapy. Aromatase inhibitor, such as AG, is probably not potent enough to block the 
ovarian estrogenic function completely, the development of GnRH analogues become 
preferable due to the fact that it can completely block the ovarian estrogen production. 
The suppressive effects can be explained by the observations that pulsatile GnRH 
administration stimulates LH and FSH while continuous infusion and receptor occupancy 
suppresses these gonadotropins, probably through receptor down-regulation and post-
receptor events (Belchetz et al., 1978; Conn, 1986; Jinnah, 1986). 
1.3 Estrogen Pool 
Hormonal therapy emphasises the modulation or decrease of the endogenous 
estrogen level, especially the control of physiological concentration of endogenous 
estrogen level in postmenopausal women. As to premenopausal women, prevention from 
long term exposure to a high level of estrogen either from exogenous xenoestrogenic 
compounds, such as TCDD contaminant or microbial products such as zearalenone or 
from an endogenous pool due to high fat diet, is desirable in prophylactic considerations. 
A brief review on the metabolism of estrogen is necessary to give a perspective view on 
the endocrine therapy. 
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High level of endogenous estrogen or excessive exposure to estrogen is generally 
regarded to be crucial and differential to the development of breast cancer. Hence, 
hypothesis proposed to bring down endogenous estrogen level has emerged to be 
beneficial as a prophylactic approach. 
Upon entering the target cells, estrogen binds to estrogen receptors. But estrogen 
is also esterified at 17B-position with oleate (from 16:0 palmitate to 22:6 
docosahexaenoate) mainly by fatty acyl CoA:steroid acyltransferase. This enzyme has the 
lowest Km for 176-estradiol (8 |iM). Androgens have higher Km and are competitive 
inhibitors. Although concentration of E2-L (lipoidal estradiol) is lower than estradiol 
(about 1/10)，esterification is unsaturable. (It serves to maintain maximal occupancy of 
ER without overloading the nuclear compartment.) E2-L releases free estradiol by 
hormone-sensitive lipase. The enzyme, acyltransferase has begun observed in bovine 
placenta and endometrium, MCF-7 cell line and human breast cancer tissue. This 
hormone sensitive enzyme can be activated by a cAMP-dependent phosphorylation. 
Besides the lipoidal estrogen pathway，endogenous estradiol level is also regulated by 
sulphotransferase. It can act on El, E2 and E3. This action results in increased water 
solubility for these steroids and thus enhancing their clearance rate. For estrogen 
receptor positive cancer cell lines, sulphurylation is the favourable route, but oxidation 
pathway (estradiol to estrone) is the favoured route for estrogen receptor negative cell 
lines (Adams et al., 1990). The sulphurylation route probably also helps to prevent 
nuclear loading by estradiol. The sulphated estrogens are then exported outside the 
targets cells. Therefore, sulphated estrogen is the most important form of circulating 
estrogen and can be found in large quantity in breast cancer tissue. Of these, only 
estrogen-3-sulphates are biologically active in estrogen receptor positive cell lines as they 
can release the free form by the action of sulphatases. It has been suspected the estrogen-
27 
3-sulphate can play an important biological role in controlling the estrogen level, 
especially in breast cancer 
where huge quantity of estrone sulphate is present. Evidences also supported that 
antiestrogen, like tamoxifen or ICI 164,384 can block the uptake of radioactivity inside 
the cell after incubation with [^H]-estrone sulphate in hormone dependent cell lines 
(Pasqualini et al., 1990). 
The major and most important metabolic route of estradiol is its oxidation to 
estrone followed by subsequent 2- or 16a-hydroxylation in liver. These two 
hydroxylation steps are largely mutually exclusive. This has particular significance in the 
control of estradiol level as these two classes of metabolites differ markedly in their 
biological properties. The product of 16a-hydroxyIation, estriol and 16a-hydroxy-
estrone, are now known to be potent uterotrophic agents under physiological conditions， 
whereas the alternative 2-hydroxylated compound, 2-hydroxy-estrone and 2-methoxy-
estrone, are devoid of such activity but do exert actions on central nervous system 
actions. Estrone sulphate is the preferred substrate for 2- or 16a-hydroxylation. This 
oxidation route of estradiol confers another importance in postmenopausal women as 
estrone becomes the predominant estrogen due to the peripheral conversion from 
androstenedione supplied by the adrenal. As the number of postmenopausal breast 
cancer patients possesses in large portion, it has been suggested that promoting the 2-
hydroxylation will show beneficial effect in the control of tumour progression as well as 
prevention (Fishman, 1980). 
Estradiol and its metabolites undergo extensive enterohepatic circulation. 
Glucuronidation occurs on the 3 position and its product estrogen-3-glucuronide remains 
in the enterohepatic circulation until it is oxidised (at 2- or 16a-) or excreted. 























































































































































































































































There is also mixed conjugation (sulphurylation and glucuronidation) and non-
conventional conjugation with minor importance. 
From this outline description of estrogen pool, one of the more promising way to 
bring down endogenous level of estrogen is to change the ratio of 2/16a-hydroxyIation 
metabolism of estrogen in liver. This is of special interest in the potential treatment 
strategy for those post-menopausal women bearing high level of serum estradiol which is 
usually associated with high risk of breast cancer incidence. Hence, consumption of I3C 
containing vegetables, such as cabbage and broccoli will be beneficial. The action 
mechanism for the I3C has drawn intensive research activities. 
1.4 Estrogen receptor 
Estrogen sensitivity is conferred by the presence of intra-cellular hormone 
receptor protein in the target tissues. These proteins bind to estrogen with high affinity, 
resulting in preferential activation of a number of estrogen induced protein expressions. 
1.4.1 General features of estrogen receptor and action mechanism 
Steroid receptor proteins have molecular masses of about 80-100 kd. Each 
monomeric unit binds a single steroid molecule, but the receptors dimerize upon binding 
to the gene sequence (the so called hormone responsive element, HRE). The subunit is 
asymmetric�not globular) and present in low amount in cells. Until recently, it was 
believed that steroid hormone receptors in unstimulated target cells were located in the 
cytoplasmic compartment (cytosol). When hormone entered the cell, it bound to the 
receptors. The receptors assume an active form by the estrogen-induced conformational 
change. The estrogen receptor-estrogen (ER-E) complex was then translocated to the 
nuclear compartment where they became associate with the hormone responsive element 
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on the chromatin. The cytosolic receptor can be prepared by extracting the target tissue 
homogenate with low-salt buffer whereas the nuclear receptor can be extracted with 
high-salt buffer. These two receptors can also be differentiated by sedimentation 
coefficient as the former will sediment in sucrose density gradient at 8S to 10 S and the 
latter type at 4S to 5S. With the advent of techniques of receptor localisation without 
homogenisation, it has been found that most steroid hormone receptors are located in the 
nucleus (King and Greene，1984) in both active or inactive state. However, the term 
"cytosolic" is still retained for that (8S) fraction that is not bound by hormone and 
extracted with low-salt buffer. In this state, the receptor forms a complex with a 90 kd 
heat shock protein (hsp), which mask the DNA-binding site and prevents interaction of 
steroid receptor with the hormone responsive element of the chromatin. The hsp90 is 
also believed to stabilise the estrogen receptor. Upon binding to ligand, hsp90 is released 
and the receptor becomes activated and dimerized and is then able to bind to hormone 
responsive element on DNA with high affinity and consequently, activate the 
transcription of mRNA. Structurally speaking, the DNA binding site (referred as TAF-1， 
transcriptional activation function 1) of estrogen receptor is distinct from the hormone 
site (referred as TAF-2, transcriptional activation function 2) as detailed by proteolytic 
cleavage analysis. It has been proposed that tamoxifen would act predominantly as 
antagonists on gene promoters on which TAF-2 was affected (Berry et al” 1990). 
1.4.2 Anti-estrogen binding site (AEBS) 
The triphenylethylene type anti-estrogen may act in part via alternate mechanisms 
that do not involve the estrogen receptor. It has been postulated that AEBS which was 
found in the cytoplasm alongside with estrogen receptors in the nucleus may be involved. 
Triphenylethylene type anti-estrogen can bind directly to the cytoplasmic AEBS (K^ 
about 1 nM), and mediate part of its anti-tumour action (Miller and Katzenellenbogen, 
1983). However, the physiological functions of AEBS is not well-defined and can be 
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only characterised with preferential binding of [^H]-tamoxifen to rat liver microsomal 
preparation in the presence of high level of DES (i.e., non-estrogen receptor binding). 
1.4.3 Physiological consideration 
Steroid hormone controls a vast number of metabolic and biosynthetic events in 
the body. Estrogen and progesterone interact to control the growth, development and 
physiology of the female reproductive tract and other organ systems. 
1.4.3.1 Uterus: uterotrophic responses 
Uterotrophic responses to estrogen can be classified into early and late response. 
The former refers to those responses induced within minutes after exposing estrogen. The 
late response can result in cellular hypertrophy and hyperplasia (true growth). Early 
responses include both biosynthetic and metabolic activities, e.g., hyperaemia, calcium 
influx, histamine release, eosinophil infiltration, increase DNA and protein precursor 
uptake, and enhanced glucose oxidation. It also includes increase synthesis of RNA and 
protein, which eventually causes the uterus to grow. For late responses, some of which 
are simply extensions of those begun during the early period. The biosynthetic activity 
in cellular hypertrophy and DNA synthesis eventually lead to hyperplasia, as uterine 
growth. 
Uterotrophic response, especially the late response, is traditionally used as an 
indicator of estrogen action in animal experiment to assess anti-estrogen action (Lauson 
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1.4.3.2 Progesterone, the physiological estrogen antagonist 
Progesterone acts to modify and redirect the cellular growth and biosynthetic 
activity of the uterus. Progesterone inhibits further endometrial proliferation induced by 
estrogen and converts the endometrium to the secretory type. The endometrium is then 
ready for implantation of the blastocyst and subsequent maintenance of pregnancy. 
However, the function of progesterone is manifested through prior elevation of its 
receptor levels by estrogen (Walter et al., 1985). Progesterone can down-regulate both 
estrogen receptor and its own receptor level (Hsueh, et al, 1976). 
The concentration of estrogen receptor is important for the manifestation of 
estrogenic action and it is maintained at a basal level due to constitutive synthesis. The 
level is also influenced by endogenous and exogenous steroids. For instance, injection of 
estradiol leads to rapid depletion of cytosolic receptors, which had bound tightly in the 
nucleus as estrogen-receptor complex. This is followed by a replenished cytosolic 
receptor through reactivation/reutilization of nuclear-bound receptor and the de novo 
synthesis of receptor molecules. The uterus is relatively insensitive to progesterone 
unless it is first exposed to estrogen. After estrogen priming, progesterone receptor 
synthesis is stimulated. This increase in the quantity of progesterone receptor results in 
progesterone responsiveness. 
Progesterone has the paradoxical effect of causing a rapid decrease in cytosolic 
progesterone receptor in guinea pig uterus (Milgrom, 1970; 1973; Freifeld, 1974) after 
withdrawal of estrogen. It is due to the fact that progesterone suppresses the synthesis of 
estrogen receptor and the synthesis of progesterone receptor is dependent on the action of 
estrogen via the estrogen receptor. Therefore, progesterone can suppress the synthesis of 
its own receptor by desensitising the uterus to estrogen. 
34 
Progesterone acts on the estrogen-primed uterus to alter the cell function and 
reproductive competence. It is regarded as a modifier of estrogen action. Progesterone 
can suppress the action of estrogen on uterine growth and vaginal cornification. This 
ability of progesterone to antagonise estrogen action involves down-regulation of 
cytosolic estrogen receptor. 
According to Clark et al. (1992), anti-estrogen can be divided into 3 groups: (1) 
short-acting antagonists, such as estriol; (2) long-acting antagonists, such as tamoxifen 
and clomiphene; (3) physiological antagonists, such as progestins, androgens and 
glucocorticoids. 
For short-acting estrogens such as estriol, they stimulate early uterotrophic 
responses but have little effect on true uterine hypertrophy and hyperplasia when injected 
in saline (Clark and Peck, 1979; Clark and Markaverich, 1982). The short-acting 
agonists do cause nuclear binding of the hormone-receptor complex for short period of 
time and thus they are able to stimulate early uterotrophic events. However, they are 
unable to maintain the receptor in the nucleus for a sufficient period of time to cause true 
uterine growth. The antagonistic action stem from the competition between estradiol-
receptor and estriol-receptor complex for functional nuclear sites. The competition 
reduces the number of effective estrogen-receptor complexes retained in the nuclear 
compartment. Triphenylethylene derivatives, such as TAM or clomiphene, are mixed 
agonist-antagonists of estrogen action (Clark and Markaverich, 1966)，which is all too 
common among the anti-steroid hormones. 
1.5 The role Of growth factors and steroid hormones in breast cancer cell 
Estrogen functions as mitogen in estrogen receptor positive breast cancer cells in 
vitro and stimulate the expression of a number of genes including those for certain 
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growth factors, secretory proteins (Clarke et al., 1991) such as insulin-like growth factor 
(IGF-1), and insulin-like growth factor 2, transforming growth factor a (TGF-a), 
epidermal growth factor (EGF). However, none of these can be responsible solely for the 
mitogenic activity stimulated by estrogen. Estrogen may influence the growth and 
differentiation of cancer cell through indirect actions. In MCF-7 cells, estrogen increases 
the secretion of platelet-derived growth factor (PDGF) (Bronzert et al., 1987). PDGF 
can, in turn, stimulate insulin-like growth factor-1 (IGF-1) production in human 
fibroblasts (Clemmons and Shaw, 1983). Thus, an additional paracrine stimulation of 
breast cancer cells could occur through the effects of tumour derived, estrogen-stimulated 
growth factors inducing stromal cells to secrete IGFs or other factors. TAM was shown 
to increase the secretion of TGF-6 by MCF-7 cells, presumably by means of its 
interaction with estrogen receptor. TGF-6 appears to be a growth inhibitor factor 
(Knabbe, 1987). Some also argued that the TGF-B may be secreted from the stroma cell 
surrounding the breast cancer cells (Butta, 1992). Pharmacological concentrations of 
estrogens such as DES (say, 50 mg, three times per day) can inhibit some estrogen-
dependent breast cancer. The action mechanism remains unclear but non-specific effects 
mediated by changes in plasma membrane fluidity appear to be involved (Clarke et al., 
1987) 
Based on hypothesis made by Ignar-Trowbridge et al. (1991)，and others (Joao et 
al., 1990; Bignon et al., 1990)，evidences have been accumulated that steroid hormones, 
including estrogens, may induce actions that are nongenomic, i.e., these actions are not 
mediated by nuclear estrogen receptor processing (Weiss and Gurpide, 1988; Smith, 
1989). It was observed that DES administration caused rapid increase in [^H]-myo-
inositol incorporation, which persisted for at least 18 hours. This stimulation can be 
suppressed by ICI164,384, a specific estrogen receptor antagonist. These changes occur 
before the onset of estrogen induced DNA synthesis. Change of phosphoinositides 
, ‘ 
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turnover appears to be mediated by estrogen receptor binding mechanism but not 
requiring RNA and protein synthesis. Ignar-Trowbridge had further shown that the 
inhibitory effect posed by TAM may be due to direct binding to phospholipid binding 
domain, rather than going through estrogen receptor mediated process. 
1.6 Alternate cytotoxic action of TAM 
As an anti-estrogen, TAM had shown alternative mechanisms such as inhibition 
of protein kinase C (PKC) and phosphodiesterase and the toxicity against MCF-7 cells. 
Tamoxifen is a synthetic triphenylethylene anti-estrogen drug that has been used 
clinically in the treatment and prophylaxis of breast cancer (Richardson, 1988; Powles et 
al., 1989; Powles et al., 1990; Fentiman, 1990; Prentice, 1990). Although tamoxifen is 
designed to act on the estrogen receptor, even estrogen receptor negative breast cancer 
cell can respond to the drug (Taylor, 1984; Etienne et al” 1989) This leads to the 
proposed estrogen-independent mode of action including inhibition of calmodulin-
2+ 2"f" 
mediated systems such as the plasma membrane (Ca + Mg )-ATPase (Celeste et al” 
1990; Joao et al., 1990)，cAMP phosphodiesterase (Lam, 1984; Rowlands, 1990) and the 
protein kinase (O'Brian et al., 1985; Bignon, 1990) that play important role in cellular 
growth regulation (Nishizuka, 1988). Some also proposed that TAM and its more active 
analogue, 4-hydroxyl-tamoxifen could inhibit lipid peroxidation in phospholipid 
liposomes (Wiseman et al., 1992). 
The enzymes, PKC and PDE have a central role in the transduction of signal from 
a variety of mediators, from hormone, cytokine, growth factor to neurotransmitter, across 
the cell membrane. Receptor occupation results in activation of the PKC via activation 
of phospholipase' C through either a G-protein mechanism or a tyrosine kinase 
mechanism. PKC can then propagate the signal through phosphorylation of protein on 
amino acid residues, say, serine or threonine. ATP acts as co-substrate for the 
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phosphorylation process and other co-factors, such as calcium and diacylglycerol (DAG) 
are required for activation. Phosphorylation is a common way to modify the properties 
of various proteins. Hence, PKC appears to regulate cell proliferation，secretion and 
gene expression. Inhibition of PKC sheds light on therapy for disease such as 
rheumatoid arthritis, cancer and even AIDS. Since most of the growth factors induced 
secretion by estrogen require PKC and PDE to propagate their signals no matter their 
receptor are coupled or not with G protein (PDGF) or tyrosine kinase (EGF, IGF). 
Hence, the PKC/PDE inhibitory action may lead to suppression of tumour cell growth. 
1.7 In vitro models utilised in breast cancer study 
The breast cancer tissue taken directly from the operation room for the 
investigation of cellular and molecular biology of breast cancer encounters several 
limitations. One limitation is that these tissues contain varying amounts of other cells 
and tissue components, including lymphocytes, blood vessels and stroma. Usually, too 
few cells are left for practical study after the isolation process. Therefore, cell culture has 
provided an appealing approach for studying the molecular and cellular biology of breast 
cancer. 
A readily available source of cultured breast cancer cells would also permit 
individualised chemotherapeutic drug sensitivity testing and allow the possibility of 
developing preferential enhancement of a patient's tolerance by raising the dose of one 
drug against another. 
Although established cell lines are derived from human breast carcinoma, its 
functions only reflect those tissues from a small subpopulation of cancer cells within the 
tumour specimen. Even so, the composition remains heterogeneous. Besides the 
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establishment of immortal cell lines, the culture conditions also constitute a highly 
selective process. Based on this, the MCF-7 cells represent only late stages of malignant 
progression and each laboratory has its own MCF-7 cell line with variable estrogen 
responsiveness. Therefore, in our study, it functions to represent the tumour as if is 
staged at the late phase of malignant progression and it also provides a handy source of 
human estrogen receptor preparation. 
The MDA-MB-231 is employed to compare the factor of estrogen receptor on 
tumour suppression induced by test compounds. 
1.8 Current development of anti-estrogen 
Of all those agents trying to bring down or even eliminate the action of estrogen 
in postmenopausal women, tamoxifen is the major clinically used anti-estrogen with 
great success. Despite the efficacy of tamoxifen treatment, most patients eventually 
develop drug resistance (Fuqua et al., 1991). The action of TAM appears to be cytostatic 
rather than cytotoxic toward cancer cells. Newer anti-estrogens, such as trioxifene, 
which is a potent anti-estrogen with low intrinsic estrogenic properties and higher affinity 
for the estrogen receptor than that of tamoxifen, was found to have an anti-tumour effect 
only comparable to that observed with tamoxifen (Witte et al” 1986 and Lee et al., 1986) 
and may even have greater toxicity than that of TAM (Witte et al., 1986). Recently, the 
compound LY 156758 from Eli Lilly, which has higher affinity for the estrogen receptor 
than tamoxifen (Black et al., 1982) failed to give responses in clinical trial. Another 
steroidal anti-estrogen, ICI 164,384 can completely inhibit the stimulatory effects of 
estradiol on uterine weight and it lacks agonist activity, it is referred to be a pure anti-
* 
estrogen. HoweVer, its hydrophobic nature limits its application as an effective drug in 
treatment of breast cancer. All of these anti-estrogens share a structural resemblance to 
estradiol and required a hydroxyl group at position equivalent to the ring A of estradiol. 
39 
The effectiveness of hormone antagonists in vivo depends on the physiological response 
being examined, and can vary in different species, organ, tissue, or cell type that is being 
examined, and on the end-point assay chosen. For example, clomiphene and tamoxifen 
cause growth of the rat uterus when administered alone but inhibit the growth-promoting 
effects of estradiol when given simultaneously (Clark and Markaverich, 1966). 
Tamoxifen was found to be an antagonist in breast cancer cells but an agonist in 
endometrial cancer cells. When the effect of tamoxifen on uterine or oviduct weight is 
measured, the drug is found to be a pure anti-estrogen in the chicken, a partial agonist in 
human and rat, and a full agonist in mouse (Furr and Jordan, 1984). It is suggested that 
part of this variation is due to the fact that the antagonists can be metabolised in either 
the liver or the target tissues. However, even this cannot completely account for the 
different response of tamoxifen in these systems. Hence, some scientists suggested that 
other action mechanism may be involved, for example, the alternate actions on PKC, 
PDE inhibitor and AEBS. All these anti-estrogens are designed to have a estradiol-like 
backbone plus a hydroxyl group at a position equivalent to ring A of estradiol for 
estrogen receptor binding and an alkylamide side chain for anti-estrogenic activity. 
The 况J indole alkaloid, yuehchukene, (YCK), which was initially developed in 
pursuit of effective oral anti-fertility agents, was tested for its potential in the breast 
cancer management. Its anti-implantation action is the result of the perturbation of 
estrogen regulated process. YCK can compete for rat uterine estrogen receptor readily, 
albeit of low binding affinity. It remains unclear as to which part of the structure of YCK 
molecule is responsible for estrogen receptor binding. Besides, the close resemblance 
between the structure of YCK and the structure of some acid condensation products of 
the anti-tumour dgent, I3C，which has chemopreventive effect in DMBA induced rat 
mammary tumour, led to the study of the possibility of YCK as a chemopreventive agent. 
With this new molecular design (different from the triphenyethylene type anti-estrogen), 
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its ability to bind to estrogen receptor, its structural similarity to I3C acid condensation 
product, it is worthwhile to investigate its role in breast cancer management. The 
objective of the present study is to evaluate the estrogenicity of YCK and assess to what 
extent can it be used as an anti-estrogens or as a chemopreventive agent for human 
application. 
1.9 Background about yuehchukene (YCK) 
Yuehchukene (YCK) is a novel to-indole alkaloid isolated from the root of 
Murraya paniculata (Rutaceae) and related species of the genus (Kong et al., 1985a). No 
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extract from the root of Murraya paniculata could effectively prevent gestation in rats 
when dosed from pregnancy day 1 to day 4 at 1.25 mg/kg orally (Kong et al., 1985a) • 
This strongly suggested the presence of anti-implantation agent in this preparation. 
Guided by the anti-implantation assay, isolation of sufficiently pure form of YCK for 
structural elucidation was finally accomplished (Cheng et al.，1985). After the 
biomimetic synthesis of YCK was finished in 1985 by Dr. K.F. Cheng (Cheng et al., 
1985), analogue synthesis as well as structure activity relationship (SAR) are studied. 
Several unique chemical features of YCK have been observed: 1) YCK has an indeno-
indole basic structure not found in other indole derivatives; 2) YCK is the product of 
dimerization from two prenylated indoles; 3) YCK could be regarded as Z7W-indole joint 
by a methylene bridge; 4) YCK is most likely a non-enzymatic condensation product 
from MBDI, its precursor. X-ray data of YCK N'-monoacetyl derivative (Kong et al., 
1985b) suggested that the pair of hydrogen atom between the two rings of the indene 
moiety are in the cw-configuration and in the same plane as the free indole. 
However, YCK was not active in marmosets, and the handful of YCK analogues 
designed to dissociate the anti-implantation effect from its estrogenicity failed to yield 
better result. It was no longer considered as a promising anti-fertility agent since 1988. 
The anti-implantation action of YCK can probably be attributed to its estrogenic 
property when considering positive results from a battery of estrogenic activity assays, 
namely, the uterotrophic assay, vaginal cornification, mitogenic action in human breast 
cancer cell line MCF-7, estrogen receptor binding and uterine ornithine decarboxylase 
induction. Indeed, YCK has fairly strong relative estrogenic potency in vivo at 4.5-8.2% 
of estradiol (Chati et al., 1991). This is particularly noteworthy as YCK, unlike other 
natural or synthetic estrogenic compounds, has neither an oxygen function nor a phenyl 
group. 
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The estrogenicity of YCK lies in the relative planarity of the two indole moieties. 
Enantio-selective synthesis of camphor-YCK enantiomers showed that only YCK with a 
R(+)-enantiomer was active in rat anti-implantation assay (Ho et al., 1991). In YCK 
racemate, methyl, but not phenyl substitution, on C-2' of the Tree' indole enhanced 
activity, whereas removal of the gem-dimethyl group rendered YCK inactive (Cheng et 
al., 1992). Introduction of mono substituents at C-7 resulted in partial recovery of 
activity. These structural constraints in fact limited the stereochemistry of the ’free’ 
indole to lie below the indenoindole plane and wedged between the gem-dimethyl group 
and the tetracyclic plane in an acute angle. Such stringent conformational requirement 
strongly suggests the involvement of specific receptor binding in the expression of YCK 
estrogenicity. 
YCK is also a very conservative molecule. Methyl- or methoxy-substitution on C-
2 and C-5, of the aromatic rings, and methyl- or alkyloxy-substitution on the indole 
nitrogens rendered YCK inactive (Chan et al., 1991). Like many other bioactive natural 
products that resist structural modification (e.g. quinine，reserpine), a more potent YCK 
analogue has yet to be made. 
The estrogenicity of YCK renders it undesirable for human application. Early 
attempts to dissociate YCK estrogenicity from its anti-implantation effect were not 
successful with the synthesis of a handful of analogues (seco- and isoseco-YCK, epi-
YCK, inverto-YCK, bisnor-YCK). Later, when uterine ornithine decarboxylase (ODC) 
was measured as an expression of estrogenic activity, it was noted that whereas YCK 
could induce ODC activity, like estradiol though weaker, the co-administration of YCK 
and estradiol could attenuate the full response of estradiol-induced activity to a level 
comparable to the action by YCK alone. It is this attenuation action and the deviation of 
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the relative estrogenic potency from the relative binding affinity that aroused our 
attention to the study of its action mechanism of estrogenicity and putative anti-
estrogenicity carried by this new molecular design which contained no oxygen atom or 
hydroxy group known to be critical in the estrogen receptor binding. 
Previous results suggested that a milder rising slope and a lower plateau value in 
the dose-response curve of YCK uterotrophic assay was not only indicative of a partial 
agonist with limited estrogenicity, but it also indicated that YCK may possess estrogen 
attenuation activity. In order to have a clear mechanistic view, the present study tried to 
demonstrate this attenuation action of YCK in 3 different bioassay models, viz. rat 
uterotrophic assay, mice vaginal smear and MCF-7 cell culture. The results gathered 
from these three studies agreed well with each other, strongly supporting the presence of 
estrogen attenuation effect as an inherent component of YCK pharmacological action. 
This finding puts YCK in the realm of a mixed agonist/antagonist. This is, to a certain 
extent, similar to the case of tamoxifen and numerous anti-estrogens, which were 
originally designed for anti-fertility purpose but then ended up as potential agents in the 
treating advanced breast cancer. 
This thesis documents the estrogen attenuation activity of YCK and provides 
some insights into the possible action mechanism. The estrogenic action is strongly 
associated with many hormonal carcinogenesis, such as breast cancer and endometrium 
cancer (MacMahon, 1974; MacMahon and Cole, 1972; Reed et al., 1985). Breast cancer 
cell line (MCF-7 and MDA-MB-231) and whole animal experiments (uterotrophic assay, 
vaginal cornification, hepatic estradiol-2-hydroxylase) were employed as in vitro and in 
vivo models to study the attenuating action of YCK. Based on its attenuation action, 
contribution of YCK in human breast cancer management is discussed. YCK by virtue 
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of its new molecular design promises much difference from the triphenylethylene type 
anti-estrogen in pharmacological action. 
It is interesting to note that some of the polymeric indole compounds obtained 
from acid condensation of I3C happen to have structural similarity to the YCK bis-indo\c 
molecular design. This prompted us to see whether they also share similar function as 
well. In this study, YCK also shares similar mode of action as I3C acid condensation 
products (I3Ca) on top of its intrinsic estrogenic function due to the affinity toward 
estrogen receptor. YCK behaves like I3Ca to bring down estrogen level by enhancing the 
hepatic estradiol-2-hydroxylase. 
Cell culture systems have been used extensively for the study of anti-estrogen and 
their structure activity relationships (Jordan and Murphy, 1990) by establishing the 
relationship between the structural and relative binding affinity to estrogen receptor as 
well as cellular response. Even with a handful of YCK analogues available, binding 
affinity toward estrogen receptor is also performed to look into the relation between 
estrogen receptor affinity and their bioactivity. 
To understand the alternate mechanism on the estrogen attenuation action of 
YCK, protein kinase C and phosphodiesterase inhibitory activity were also examined. 
This could reveal another facet of the multiple functions associated with YCK. 
Moreover, a structural comparison between some known PKC/PDE inhibitors，e.g., 
staurosphorine or K252C from fungus Nocardiopsis sp. K-290 (Davis et al” 1992) with 
YCK further confirm the possibility that YCK can also inhibit the PKC and PDE action. 
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2. Materials and methods 
2.1 Studies using whole animals 
Sprague-Dawley rats were supplied by the University Animal House. They were 
randomly bred and fed with Purina rodent chow and water ad libitum in an air-
conditioned animal house. Environment for animals was kept clean and set to illuminate 
with constant light-dark cycle (0900 to 2100 hour daily). For anti-implantation and 
uterotrophic assay, a consistently high fertility rate of over 98% was maintained 
throughout the year. Mated rats were numbered and assigned to experimental groups 
sequentially. 
2.1.1 Uterotrophic assay in rats 
Female Sprague-Dawley rats at 18 days old were bilaterally ovariectomised and 
allowed to rest for 1 week. They were dosed orally, twice daily over 3 days with a vehicle 
volume of 0.2 ml per 100 g body weight containing testing compounds as specified. 
Twenty four hours after the last dose, they were etherised and the uteri were removed at 
the cervical junction. After trimming free of fat, each pair of uterus was first weighed 
with uterine fluid inside. Then the cervical part was excised, the fluid drained and the 
uteri were blotted before weighing again. In this way, the uterine fluid was exaggerated 
by a small fraction due to the cervical tissue but the margin of error was the same for 
every pair. Tissues were weighed in a digital balance that reads 0.1 mg. During autopsy, 
the successful removal of the ovaries, the patency of the vagina and its exfoliative 
cytology were noted. 
The increase in uterine weight was a measure of uterotrophic responses to 
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estrogenic action. Each group of animal contained 5-6 rats. Drugs were dissolved in 
ethanol as stock. Stock solution of test compounds were diluted to required dose such 
that they contained a final concentration of 10% of ethanol. Vehicle also consisted of 
10% of benzyl benzoate (B.B.) and 80% olive oil. For those test compounds insoluble in 
ethanol (e.g., I3Ca, N,N'-dimethyl-YCK), drugs were first dissolved in DMSO and the 
appropriate amount of ethanol was then added. The ethanol part in the vehicle was 
replaced by DMSO/ethanol (1:1) solution. 
When the uterine tissues were recovered for enzyme assay or preparation of 
estrogen receptor, they were processed immediately. On the contrary, when livers were 
removed from the same rat for enzyme assays, they were excised, numbered and plunged 
directly into liquid nitrogen. These frozen livers were stored at -80°C until use. 
2.1.2 Anti-implantation assay in rats 
Eight week-old female Sprague-Dawley rats, 200-220 g, were supplied on the 
morning when evidence of mating was indicated by the presence of post-coital plug. 
This was designated as day 1 of pregnancy (PDi). The animals were then dosed orally in 
the morning with 1 ml of drug solution or vehicle for every 250 g body weight from 
PDi-4, or otherwise assigned. They were autopsied on PDg. The number of pregnant 
animals was recorded. The uteri were removed, trimmed and photographed, then 
preserved in Bouin fixative. The absence of implantation sites was an indication of anti-
implantation activity. All YCK analogues were dosed to achieve an 'all or none' end 
point. Each group of animal contained at least 5 rats. 
All test compounds were dissolved in ethanol as stock and diluted to give a final 
concentration of 10% of ethanol in vehicle. Vehicle composition was the same as those 
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mentioned in uterotrophic response. 
2.1.3 Vaginal smear in mice 
This study was carried out in the Department of Veterinary Physiology, The 
University of Sydney, in collaboration with Professor Grant Stone, using randomly bred 
mice of the QS strain 
Mice were ovariectomised at 25-30 g body weight and primed with 1 [ig estradiol 
subcutaneously one week later. Animals received further priming doses every 2 weeks 
unless used. For in vitro binding studies, animals received two subcutaneous doses of 
0.1 mg E2 24 hours apart, and were killed by barbiturate overdose 48 hours after the first 
injection. For in vivo tests of the estrogenic/anti-estrogenic activity, animals received 
intravaginal doses of E2 or YCK in 100 of 0.9% (w/v) saline containing 0.03% 
DMSO and 0.5% ethanol, between 0900 and 1000 on days 1 and 2. Smears were taken 
from the dorsal wall of the vagina at 1000 and 1600 hours on day 4，stained with 1% 
(w/v) methylene blue and scored positive if they contained nucleated epithelial and/or 
cornified cells and no leukocytes. Control animals received vehicle only. 
2.2 Studies using human breast cancer cells 
2.2.1 MCF-7 cell culture 
MCF-7 cell line was obtained from American Type and Tissue Culture Collection 
(ATCC). MCF-7 cells (Soule et al., 1973) were delivered from pleural effusion of 
human breast adenocarcinoma carrier (aged 69; female; Caucasian). They retained 
characteristics of differentiated mammary epithelium, including ability to process 
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estradiol via cytoplasmic estrogen receptors. MCF-7 cells have been used for many tests 
of response to steroids and analogues, for example, anti-estrogens (Black et al., 1981; 
Siiteri, 1984; Jordan and Murphy, 1990)，for characterisation of new anti-estrogens 
(Blondeau and Robel, 1975), for induction of specific secreted proteins (Rodbard and 
Feldman, 1975; Duller et al.，1976) and induced secretion of EGF (Terenius, 1970). 
MCF-7 cells obtained from ATCC were maintained in phenol red free RPMI1640 
medium with 5% (v/v) stripped (see section 2.2.1.1.4) fetal calf serum (Gibco) in 
150-cm^ Corning T-flasks, incubated at 37®C and 5% CO2. 
Stripping of serum can remove most of the steroids in serum and phenol red 
produces estrogenic contaminant (Leake et al., 1987). This precaution was critical to 
observing the estrogenic sensitivity of MCF-7 cell. 
J 
2.2.1.1 Measurement of cell number 
. < 
Growth of this estrogen responsive cell line, MCF-7，can be stimulated by 
estrogen. This property is useful to assess the estrogenicity of unknown compounds in 
terms of cell growth. Cell number was estimated by 3 different methods, viz., 
haemocytometer, H33258 fluorescent dye and [ H]-thymidine incorporation. They all 
gave similar results. However, the first 2 methods seemed to give more stable result due 
to limitations of our facilities. 
2.2.1.1.1 Cell count with haemocytometer 
2 
Experiments were run in 25-cm culture flasks containing 5 ml of culture 
medium. Flasks were seeded with approximately 50,000 cells each and were incubated 
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at 37®C in humidified 5% CO2 incubator for 4 days. The medium was replaced fresh 
every other day. On the fifth day, medium was replaced and test compounds as solutions 
in 5 ml of ethanol or DMSO were added to give the required final concentrations. 
Control flasks obtained the vehicle (either ethanol or DMSO) only. Incubation was 
continued for five days. In due course, the medium containing the required concentration 
of test compounds were replaced every other day. On day eleven, cells were harvested 
with 0.05% trypsin-0.02% EDTA in phosphate buffer saline (PBS). Viable cell counts 
were made under phase contrast on haemocytometers using the Trypan Blue dye 
exclusion methods. 
In some experiments, the flask was seeded with approximately 30,000 cell each 
and incubated for 2 days before test compounds were added. This was necessary due to 
the disparity in cell cycle. Any detail procedure deviated from this standard procedure 
was mentioned in individual figure. Trypan Blue solution was prepared by dissolving 
0.1 % (w/v) trypan blue in PBS. 
2.2.1.1.2 Cell number estimated by DNA content in culture using Hoechst 33258 
Cell seeding and incubation procedure were run as mentioned in section 2.2.1.1.1. 
However, DNA content from each flask was quantitated with the fluorescent dye H33258 
according to the method of Labarca and Paigen (1980) with slight modification. Briefly, • ‘ 
cells were washed twice with PBS and solubilised by adding 1 ml of SDS solution (0.2% 
(w/v) in 10 mM Tris-Cl, 100 mM NaCl，10 mM EDTA, pH 7.0). 100 |uil aliquot of 
solubilised cells was added to 2.4 ml of PBS with 1 M NaCl, pH 7.4 containing 1 mg/ml 
of H33258. The fluorescence enhancement at 460 nm was read with Perkin-Elmer 
LS50B spectrofluorimeter using 350 nm as excitation wavelength. DNA content was 
quantified from the calibration curve constructed by thymus DNA solution. 
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2.2.1.1.3 Cell number estimated by [ H]-thymidine incorporation 
Approximately 1.4x10^ cells were plated directly into 24-well culture plate 
(Corning) and incubated for 24 hours with phenol red indicator-containing medium with 
5% dextran-coated charcoal-stripped calf serum. On the following day, the medium was 
changed to phenol red indicator-free medium with the same concentration of serum, and 
subsequent changes were made for 2 more days. Twenty four hours later, medium 
containing test compounds was added and changed daily as the cells were allowed to 
grow for 5 days. On day 5, cells were harvested for DNA synthesis assay (Leake et al., 
1987; Murphy et al” 1991). Briefly speaking, the cells were pulsed with [ H]-thymidine 
(5 |iCi/ml) only for the final 2 hours of incubation and then washed thoroughly with ice-
cold PBS. After addition of 1 ml of ice-cold 10% TCA to each well, the cells were 
sonicated for 1 minute or until over 80% of the cells were broken (checked in a phase 
contrast microscope). The precipitate was collected on a Whatman GF/C filter and 
washed with 10 ml of ice-cold 10% TCA. The filter was placed into the scintillation 
insert vials. After drying at lOO^C for 15 minutes, 4 ml scintillation cocktail (0.4% PPO; 
0.04% POPOP; 0.33% Triton X-100 in toluene) was added. The radioactivity was 
measured by a Beckman LS1801 liquid scintillation counter. 
2.2.1.1.4 Preparation of dextran coated charcoal stripped serum 
To study the effect of estrogen or estrogenic compounds induced growth requires 
prior removal of steroid factors or other estrogenic factors in serum and medium. 
Therefore, phenol red free medium (Sigma) was employed to prevent the phenol red 
contaminant from interfering the estrogen sensitivity. Fetal calf serum was stripped 
according to the method of Leake et al. (1987). Briefly, dextran-coated charcoal was 
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prepared by incubation overnight at with Norit A charcoal (Serva) and dextran T-70 
(Pharmacia) in 0.25 M sucrose, 1.5 mM MgCl2，10 mM HEPES, pH 7.4 at final 
concentrations of 0.25% and 0.0025%, respectively. A volume of the dextran-coated 
charcoal (DCC) equivalent to that of the serum to be stripped was centrifuged (500 g for 
15 minutes) to pellet the charcoal. Supernate was decanted and equal volume of serum 
was added and mixed thoroughly. It was incubated at for 12 hours before 
centrifugation to pellet the charcoal. Supernates were then subjected to filtration to 
remove trace amount of charcoal. All procedures were carried out asceptically. 
2.2.2 MDA-MB-231 cell culture 
This is one of a series of breast tumour lines (ATCC HTB 23 to 26) isolated from 
pleural effusions and characterised by R. Cailleau et al. (1974). MDA-MB-231 was 
human breast adenocarcinoma. They form poorly differentiated adenocarcinoma grade 
in in nude mice consistent with breast carcinoma. It is a hormone-independent (estrogen 
receptor negative) breast cancer cell line. 
This cell line was obtained from ATCC. It was maintained in similar condition as 
did the MCF-7 cell line, except that the serum needed not be stripped and the medium 
contained phenol red as pH-indicator. In this bioassay，cell number was quantitated by 
DNA content with H33258 fluorescent dye as mentioned in section 2.2.1.1.2. 
For intervention of MDA-MB-231 cell growth by various compounds, all 
experiments were conducted with similar procedure as those mentioned in MCF-7 cell 
growth response experiment except minor change of cell number and drug treatment 
duration in some experiments. 
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2.3 Studies using steroid receptors 
2.3.1 Rat uterine estrogen receptor 
Uterine cytosolic estrogen receptor binding was assayed according to the 
procedure of a [^H]-Estrogen Receptor Assay Kit (New England Nuclear) with the 
following preparation scheme. Briefly, immature female Sprague-Dawley rats, 20-24 
day-old, were killed by cervical dislocation and uteri were rapidly removed, trimmed free 
of fatty tissue, blotted and weighed. Uteri were pooled and homogenised (50 mg/ml) in 
ice-cold 50 mM Tris-Cl buffer, pH 7.4. The homogenate was centrifuged at 35,000 g for 
1 hour at Protein concentration was adjusted to 2 mg/ml using Bradford's method 
a 
(Bradford, 1976). One to three nM [ H]-estradiol was utilised to saturate the binding on 
estrogen receptor without YCK. Stock ethanol solution of YCK in appropriate 
concentration was added in 3 卞1 aliquots to the test tube containing 100 of freshly 
prepared cytosol and 50 of labeled estradiol with a final concentration of one to three 
nM of estradiol. A displacement curve with increasing concentrations of YCK (0.1 nM 
to 100 ^iM) was thus obtained. In another experiment, pretreatment of the cytosolic 
, ‘ 
receptor with YCK was performed by incubating the receptor preparation with various 
concentrations of YCK under the same conditions. After 20 hours, 3 nM labeled 
estradiol was added and incubated for another 20 hours. Then 300 \i\ dextran-coated 
charcoal suspension from supplier (New England Nuclear) was added and incubated for 
15 minutes. 一 T h e charcoal was centrifuged at 1500 g for 15 minutes. Supernates were 
. ‘ 
measured for radioactivity in 2 ml scintillation cocktail (0.4% PPO; 0.04% POPOP; 
0.33% Triton X-100 in toluene) by Beckman LS1801 liquid scintillation counter. 
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2.3.2 Mice uterus and vaginal estrogen receptor • • 
This work was carried out in collaboration with Professor Grant Stone, 
Department of Veterinary Physiology, The University of Sydney, using randomly bred 
mice of the QS strain. 
Mice uteri and vaginae were dissected onto ice, minced with scissors and 
homogenised with 10 volumes Tris-Cl (10 mM), EDTA (1 mM), NaN3 (0.005 M), 
NaMo04 (10 mM) and dithioerythritol (1 mM) at pH 7.4 using an Ultra Turrax 
(Germany) homogeniser. The homogenate was centrifuged at 10,000 g and then at 
100,000 g to yield the cytosol. Aliquots of the [^H]-estradiol were dried under nitrogen 
and the residue dissolved in the homogenisation buffer so that the final concentration in 
incubations was 2 nM. YCK and estradiol solutions were prepared from their respective 
stock solutions and contained 0.03% DMSO and 0.5% ethanol in homogenisation buffer. 
Incubations were carried out for 16 hours at 4®C and bound and free steroid was 
separated by the addition of 500 |j1 of charcoalidextran (0.25%:0.025%). Corrections 
were made for non-specific binding. 
2.3.3 MCF-7 cell estrogen receptor 
2.3.3.1 MCF-7 whole cell estrogen receptor binding 
Assay was based on the method of Jones et al. (1992). To each well of the 
Corning six-well tissue culture plate, approximately 2x10^ MCF-7 cells in 5 ml of 
culture medium were added. The medium was changed every other day. On day three, 
the medium was aspirated and replaced by serum free medium. The next day, the 
3 
medium was replaced by serum free medium but containing 2 nM [2,4,6,7- H]-estradiol 
, I 
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(prepared by adding 67 \i\ of 1.5 ]aM [^H]-estradiol (58 Ci/mmol)). Stock solutions of 
test compounds were added in 5卞1 aliquots of ethanol or DMSO. Experiment was done 
in triplicate. The control wells in each plate received 5 pi vehicle. Non-specific binding 
was checked by the addition of 5 |LI1 of 120 pM of estradiol, yielding a final concentration 
of 0.12 i^M "cold" estradiol. All were then incubated at 37®C for 60 minutes in 5% CO2 
incubator. After this, medium was aspirated and the cell layer was washed with ice-cold 
PBS twice. Finally, 1 ml of ethanol was added to each well and incubated at room 
temperature for 20 minutes. An aliquot of 800 |il of ethanol from each well was 
transferred to 4 ml of scintillation cocktail (0.4% PPO; 0.04% POPOP; 0.33% Triton X-
100 in toluene) and radioactivity was measured by Beckman LSI801 liquid scintillation 
counter. 
It should be noted that the incubation at 37^C for 60 minutes is sufficient to 
perform the binding study. Traditionally, when cytosolic or nuclear fraction to be 
assayed is warmed to 30^C for 30 minutes in the presence of varying concentration of 
labeled estradiol, endogenous (nonlabeled) steroid dissociates from occupied receptor 
sites. The added labeled ligand then exchanged for the receptor sites (Clark et al” 1992). 
This type of receptor binding study can estimate the total receptor sites (bound plus 
vacant) and thus termed ‘exchange assay，. Researchers have commonly used the 
exchange assay to compare with receptor assay at 4®C, 20 hours to distinguish between 
filled receptor sites and empty sites. However, the purpose of choosing this system was 
to demonstrate that YCK could diffuse freely through cell membrane. Besides, this could 
examine whether YCK undergoes structural change upon entering the cell when 




2.3.3.2 Cytosolic estrogen receptor preparation from MCF-7 cell 
Cells from 8 near-confluent 150-cm culture flasks were pooled by a 8-10 
minutes incubation at 37®C with 0.05% trypsin-0.02% EDTA in PBS. The pooled cells 
were then washed with PBS at 4®C once and then washed with homogenising buffer (50 
mM Tris-Cl, 0.1% monothioglycerol (MTG); pH 7.4). The cell pellet was then 
suspended in 0.5 ml of homogenising buffer and homogenised in a Duall all homogeniser 
(Kontes). The homogenate was centrifuged at 105,000 g for 1 hour at 4®C. The 
supernatant fraction (cytosol) was immediately used for the receptor binding assay after 
adjusting the protein content to about 1.5 mg/ml. The competitive binding study was 
carried out by incubating aliquots of the cytosolic preparation (100 \i\) with 3卞1 aliquot 
of various concentration of radioinert tested compounds by adding 50 |il specified 
concentration of [2,4,6,7-^H]-estradiol. The tubes were placed in a shaking water bath at 
4®C for 20 hours. Dextran-charcoal suspension (300 ml) were added and incubated for a 
further 15 minutes at 4®C. Reaction mixture was then centrifuged at 1500 g for 15 
minutes to pellet the charcoal. Aliqots (300 |il) of supernatant were transferred to 
scintillant (0.4% PPO; 0.04% POPOP; 0.33% Triton X-100 in toluene) and their 
radioactivities were measured by liquid scintillation counter. 
2.3.4 Progesterone receptor binding in MCF-7 cell 
The same procedure as mentioned in 2.3.3.2 was used to prepare the cytosol from 
MCF-7 cell and construct the displacement curve. But the labeled compound was a 
potent synthetic progestin, R5020. [^H]-R5020 at 0.4 to 0.6 nM was utilised as specified 
in the legend of respective figure. 
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2.3.5 Rat hepatic anti-estrogen binding site (AEBS) 
Liver lobes were removed from 200-250 g female Sprague-Dawley rats after ether 
anaesthesia and homogenised in 12 volumes of ice-cold buffer (10 mM Tris-Cl, 1.5 mM 
EDTA, 20 mM sodium molybdate, 10% glycerol, pH 7.5). The homogenate was 
centrifuged at 20,000 g for 30 minutes and the supernate was stored at -70^C (Hwang, 
1986). 
The supernate prepared from rat liver was diluted with buffer (final protein 
concentration 2.0 mg/ml) and incubated with approximately 2 nM [ H]-tamoxifen (10 
^1) in the absence or presence of various competing ligand (TAM or YCK in 10 \i\ of 
ethanol) in a final volume of 520 iliI. All assay tubes contained 1 fiM DES to eliminate 
binding to estrogen receptors. After incubating for 16 hours at 0.25 ml dextran-
coated charcoal (prepared as mentioned in section 2.2.1.1.4 was added and further 
incubated for 15 minutes. Then the charcoal was centrifuged at 1,500 g for 15 minutes. 
Supernate was added to 4 ml of scintillation cocktail (0.4% PPO; 0.04% POPOP; 0.33% 
Triton X-100 in toluene) and measured for radioactivity by liquid scintillation counter. 
Under the current condition of binding assay, the microsomal preparation could bind 
more than half of the total counts, while only 14.5% of total counts was due to non-
specific binding. In the presence of DES, 96% of specific binding to AEBS remained. 
Cold TAM displacement of labeled ligand was tested between 0.3 nM to 1.8 |iM. 
2.3.6 Estrogen receptor content estimation by enzyme immunoassay (EIA) 
The procedure to quantitate the ER content of human breast cancer cell lines is 
adopted from a commercially available assay system (Abbott EIA Monoclonal system). 
Cytosol from MCF-7 cells was prepared as described in section 2.3.3.2. After preparing 
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the cytosolic estrogen receptor, the remaining crude nuclear pellet was resuspended in 
buffer containing 50 mM Tris-CI, 0.1% monolhioglyccrol (MTG), pH 7.4，10% glycerol, 
0.8 M KCl. The mixture was incubated for 1 hour at with resuspension by pasteur 
pipette every 15 minutes. The suspension was then centrifuged at 180,000 g for 30 
minutes. The resulting supcrnatc was used as nuclcar estrogen rcccptor preparation. 
Protein concentration of cytosolic and nuclear estrogen receptor preparation were 
measured according to Bradford's method (1976) and appropriate dilution to 1.5 mg/ml 
was made to perform the assay according to the manual of Abbott EIA-ER Monoclonal 
system. Briefly, 100 |al of estrogen receptor preparation (cytosolic or nuclear) was added 
to well provided by the supplier Which had been pre-cooled in ice bucket. 100 \i\ of 
control with known estrogen capacity was resuspended accordingly and was added to 
well. The specimen diluent (100 \x\) was then added to each of the well containing 
specimen or control. 200 |li1 of 0，5, 25, 100 and 250 fmol/ml standards were prepared 
freshly and pipetted to their assigned wells. Monoclonal antibody-coated bead was 
added to each well containing standard, specimen or control. Incubation was carried out 
at 4®C for 18 hours in refrigerator. After incubation, liquid in well was aspirated and 
washed with 4 to 6 ml of distilled water twice. 200 of ‘ER-Conjugate，i.e., enzyme 
linked secondary antibody, was dispensed into each well containing a bead. It was then 
put into 37®C water bath and incubated for 1 hour. Five to ten minutes before end of 
incubation, o-phenylenediamine-2HCl (ODP) substrate solution was prepared by 
dissolving the supplied tablet according to manual. At the end of incubation, each bead 
was washed with 4 to 6 ml of distilled water twice. Excess liquid was removed by 
aspiration. With flip transfer to properly labeled reaction tubes immediately, 300 |il of 
well-mixed ODP substrate solution was added to each tube. Reaction tubes was 
incubated in dark for 30 minutes at room temperature. Reaction was stopped by adding 1 
ml of sulphuric acid to each tube and mixed thoroughly. Absorbance was read at 492 nm 
within 2 hours. Absorbance of standard and specimen was measured either by Quantum 
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IjTM Analyser (Abbott Laboratory) or Bio-Rad 3550 microplate reader. 
2.4 Enzyme studies related to estrogen metabolism 
2.4.1 Rat uterine ornithine decarboxylase (ODC) 
Female Sprague-Dawley rats, 20-24 day-old, were injected with tested 
compounds subscutaneously in 0.2 ml of olive oil with 10% ethanol at optimal dose as 
recommended by literature (Korach et al., 1979) and sacrificed after 20 hours. High 
speed uterine cytosolic preparations were incubated with 40 |iM of L-[l-^^C]-ornithine 
hydrochloride (50-60 mCi/mmol, Amersham) in the Tris-pyridoxal phosphate-
dithiothreitol buffer, pH 7.4. Incubations were carried out in 15 ml home-made glass 
bottles and sealed with a rubber stopper. Each bottle contained a polyethylene counting 
vial. The released was absorbed in 0.25 ml methylbenzethonium hydroxide 
contained in the counting vial. The bottles were incubated at 37®C for 1 hour at which 
time 1 ml of 10% trichloroacetic acid was injected through the rubber septum directly 
into the reaction mixture. The bottles were then counted in 4 ml of scintillant. Protein 
concentrations were determined by Bradford's (1976) method. Enzyme preparations 
from different groups were adjusted to the same protein concentration prior to assay. 
2.4.2 Rat hepatic ethoxyresorufin O-deethylase (EROD) 
Female Sprague-Dawley rats, 18 day-old, (3-5 rats per treatment) were dosed 
orally with indole-3-carbinol acid condensation product (I3Ca) prepared in the laboratory 
according to Baldwin and Leblanc (1992). YCK, MBDI and estradiol were dosed at 
concentrations of 1，13.2 and 0.03 mg/kg body weight respectively. All test compounds 
were dissolved in DMSO and added to 9 parts of olive oil for dosing. Control group only 
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received olive oil with 10% DMSO. Rats were killed at specified time by cervical 
dislocation, their livers were excised, frozen in liquid nitrogen and stored at -80®C until 
use. Uteri were recovered for concurrent uterotrophic assay and ODC assay as 
mentioned above. Ethoxyresorufin 0-deethylase activity functions as an indicator of 
cytochrome CYPIA activity (Lubet, et al” 1990). It was assayed according to the 
method of Pohl and Fouts (1980) with minor modifications. Individual rat livers were 
thawed and homogenised in ice-cold homogenisating buffer (10 mM HEPES, 1 mM 
EDTA, 1 mM DTT, 10% glycerol; pH 7.4) with an all glass Duall homogeniser. 
Microsomes were obtained by differential centrifugation (van der Hoeven and Coon, 
1974). Briefly, the livers were homogenised with 4 volume of buffer and was 
centrifuged at 1,200 g，4®C for 30 minutes. The supernate was then subjected to 
centrifugation at 105,000 g，4®C for 1 hour. The resulting microsomal pellets were 
suspended in same volume of 0.1 M potassium pyrophosphate buffer, pH 7.4 containing 
1 mM DTT, 1 mM EDTA and 20% (v/v) glycerol. The mixtures were further 
centrifuged at 105,000 g，4®C for 40 minutes. The microsomal pellets were resuspended 
in 0.1 M potassium phosphate with 1 mM EDTA, 1 mM DTT, 20% glycerol; pH 7.4 and 
adjusted to a protein concentration of 10 mg/ml with Bradford's method (1976). 
Microsomes were then stored at -80®C. For the EROD assay, 50 |ng protein was 
incubated in 1.0 ml of 50 mM potassium phosphate buffer (pH 7.5) containing 0.1 mM 
MgS04, 1.6 mg BSA and 1.5 mM of ethoxyresorufin. Reaction was initiated by the 
addition of a NADPH regenerating system (1 unit of glucose-6-phosphate 
dehydrogenase, 0.28 mM 6-NADP and 2.5 mM glucose-6-phosphate). Reaction 
mixtures were incubated in 37®C water bath and stopped after 15 minutes by 
precipitating the protein with 1 ml of methanol. The formation of resorufin was 
measured by fluorescence of the supernatant fraction with excitation wavelength of 550 
nm and emission wavelength of 585 nm. The resorufin concentration was read from the 
standard curve constructed by resorufin. 
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2.4.3 Rat hepatic estradiol 2-hydroxylase 
Estradiol 2-hydroxylase activity was measured by quantitating the formation of 
^H20 from 176-[2-^H(N)]-estradiol (20 Ci/mmol) in the presence of the NADPH 
regenerating system mentioned above. Briefly, 50 \ig microsomal protein (section 2.4.2) 
was incubated in 1.0 ml of 50 mM potassium phosphate buffer (pH 7.4) containing 0.1 
mM MgS04, 1.6 mg BSA and 40 nM radioactive labeled estradiol. After initiating with 
the NADPH regenerating system, the reaction mixture was incubated at 37®C for 10 
minutes. Reaction was terminated by the addition of 200 ml of 30% trichloroacetic acid 
(TCA) and 1 ml of dextran-charcoal suspension (0.5% Norit A and 0.05% dextran T-70 
in 50 mM Tris-Cl; pH 7.4). After incubation at 4®C for 15 minutes, all these mixtures 
were centrifuged at 1500 g for 15 minutes. Aliqots (0.5 ml) were transferred to 4 ml of 
scintillant (0.4% PPO; 0.04% POPOP; 0.33% Triton X-100 in toluene) and the 
radioactivity was counted by liquid scintillation counter. Background counts were 
determined by blank controls and removed from results presented. 
2.4.4 MCF-7 cell estradiol-2-hydoxylase. 
For the 2-hydroxylase activity measurement of MCF-7 cell, confluent MCF-7 
cells in 75-cm^ flasks, grown in phenol red free RPMI1640 medium supplemented with 
5% stripped fetal calf serum, were treated with various test compounds in ethanol or 
DMSO. The final solvent concentration in culture medium was 0.1%. Control group 
received 0.1% vehicle only. After 4 to 5 days of culture, cells were harvested and seeded 
into 25-cm^ flask at 1x10^ cell per flask density and the same treatments were continued 
for another 3 days. Thirty six hours before the addition of radioligand (176-[2- H(N)]-
estradiol, 20 Ci/mmol), estradiol treated groups were washed with PBS three times and 
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fresh medium free of estradiol was refed. After this, all received 1 ^Ci of radiolabeled 
substrate/25-cm^ flask in 5 ml of medium and incubation continued for 24 hours at 
a 
37®C, in a 5% CO2 incubator. Non-enzymatic release of H2O was estimated by 
parallel incubation of cells that had been fixed by 70% ethanol for an hour. 
2.4.5 Human placental microsomal aromatase activity 
. < 
Human placenta was obtained from Prince of Wales Hospital within one to three 
hours of vaginal delivery of healthy, full term infants. It was processed immediately at 
4®C. The placental microsomes were washed and prepared according to Ryan (1959) 
and Bullion (1990) with minor modification. The cotyledon tissue was rinsed with 1% 
KCl in 67 mM phosphate buffer (pH 7.4) and homogenised in a Waring blender in 
freshly prepared 67 mM phosphate buffer containing 0.24 M sucrose, 0.5 mM DTT (pH 
7.4). The homogenate was centrifuged at 12,000 g for 20 minutes at The supernate 
was collected by decantation and centrifuged at 105,000 g for 60 minutes at 4®C. This 
sedimented microsomal pellet was resuspended to homogenised in glycerol-containing 
buffer (20% v/v glycerol, 0.5 mM EDTA, and 1 mM DTT) and centrifuged again at 
105,000 g for 40 minutes at 4®C. This washed pellet was homogenised again in glycerol 
containing buffer and diluted to 50 mg/ml for storage at -80®C. Protein content was 
estimated by Bradford's method (1976). 
Human placental microsomal suspension ranging from 3-25 pg, was preincubated 
at 37®C in 1.9 ml of 67 mM phosphate buffer containing 5 mg BSA, 0.5 mM EDTA 0.5 
mM DTT and substrate ([ 1 B-^H]-androstenedione, 40 nM) with or without putative 
inhibitor (YCK or AG). After 2 minutes, 5 mg NADPH in 0.1 ml of phosphate buffer 
was added (time zero) and the incubation was allowed to proceed for another 5 minutes. 
It was then terminated by the addition of 0.25 ml of 20% trichloroacetic acid. A 
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suspension of 5% activated charcoal (0.5 ml) was added and shaken for 30 minutes. 
After centrifugating at 3,000 rpm to pellet the charcoal suspension, 1 ml of supernate was 
mixed with 10 ml of scintillant and the radioactivity was measured by Beckman LSI801 
liquid scintillation counter. 
2.5 Enzymatic studies related to signal transduction 
2.5.1. Inhibition of Protein Kinase C (PKC) activity of MCF-7 cell and protein 
phosphorylation 
Inhibition of protein kinase C in vitro 
Subconfluent cells (approximately 4x10? cells) were rapidly harvested in cold 
PBS and homogenised in freshly prepared 20 mM Tris-Cl (pH 7.4), 2 mM EDTA，2 mM 
EGTA, 5 mM dithiothreitol, 2 mM phenylmethylsulfonyl fluoride (PMSF) and 0.1 mM 
leupeptin. The cell lysate was centrifuged for 1 hour at 105,000 g. The supernate was 
used to perform the assay with a commercial kit provided by Amersham (Protein kinase 
C enzyme assay system; RPN 77) with minor modification. Protein kinase C was 
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assayed by measuring the incorporation of P from [7- P]ATP into a specific peptide 
substrate activating with the phorbol 12-myristate 13-acetate (PMA) and appropriate 
amount of calcium and magnesium. 25 |il of assay buffer containing 50 mM Tris-Cl (pH 
7.5), 3 mM calcium acetate, detergent-dispersed solution of 2 mole% L-a-phosphatidyl-
L-serine and 6 \ig/m\ PMA in 50 mM Tris-Cl, 225 |jM peptide and 7.5 mM DTT, was 
» 
added to 25 |il appropriate dilution of MCF-7 cell lysate supernate and mixed well. To 
demonstrate the inhibitory action of TAM and YCK, 3 \i\ of TAM or YCK dissolved in 
ethanol was pipetted to the reaction mixture. Reaction was initiated by the addition of 25 
of magnesium [^^P] ATP buffer with 150 mM ATP (10 mCi/ml) and 45 mM 
magnesium acetate and reaction mixture was incubated for 15 minutes in 25 water 
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bath. Reaction was terminated with 100 \i\ stop reagent provided. The phosphorylated 
peptide was separated and isolated by Whatman P-81 paper washing with 5% (v/v) acetic 
acid twice. The incorporation of P into the peptide substrate was measured by 
Beckman LS-1801B liquid scintillation counter. 
Sample preparation for phosphorylation pattern analysis 
Subconfluent MCF-7 cell (approximately 1x10^ cells/35mm dish) were washed 
twice in a phosphate-free Krebs-Ringer buffer containing 20 mM 4-(2-hydroxyethyl)-l-
piperazineethanesulfonic acid, pH 7.3, 0.1% bovine serum albumin, and 0.2 % glucose 
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and incubated for 2 hours at 37®C in 1 ml of the same buffer containing 50 mCi of [ P]-
phosphoric acid. Test compounds were then added for a further 30-min period. Cells 
were washed twice with cold PBS, and 10% TCA was added. TCA-precipitated proteins 
were dissolved in 150 |li1 of electrophoresis sample buffer containing 60 mM Tris-Cl, pH 
6.7, 2% SDS, 8% glycerol，2% B-mercaptoethanol, and 0.005% bromophenol blue. 
Sample were then boiled for 5 minutes at boiling water bath. Proteins were fractionated 
by electrophoresis on 5% and 12% (w/v) discontinuous SDS-polyacrylamide slab gel 
(Laemmli and Favre, 1973). After fixation of proteins with cold TCA and staining with 
Coomassie blue, the gel was dried and then exposed to Hyperfilm MP for 72 hours. 
Sodium Dodecyl Sulphate / Polyacrylamide Gel Electrophoresis (SDS/PAGE) 
Acrylamide, N,N'-methylenebisacrylamide, ammonium persulphate, were 
obtained from Bio-Rad, N,N N，’N，-tetramethylethylenediamine (TEMED) was 
purchased from Sigma. The apparatus (Mini PROTEAN 11) was a product of Bio-Rad. 
The buffer system adopted here was based on the method of Laemmli and Favre (1973). 
Separating gel (12%) prepared in a slab gel mould (70x800x0.75 mm) was overlayed 
with a 5% stacking gel. Electrophoresis was carried out at room temperature with a 
constant current of 20 mA. The separating gel buffer was 0.375 M Tris-Cl, pH 8.8, while 
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the stacking gel buffer contained 0.125 M Tris-Cl, pH 6.8. Sample buffer contained 60 
mM Tris-Cl, pH 6.7，2% SDS, 8% glycerol, 2% 6-mercaptoethanol, and 0.005% 
bromophenol blue. Electrode buffer consisted of 0.1% SDS, 0.192 M glycine, 25 mM 
Trisma base (Sigma Chem.)，pH 8.3. Electrophoresis was stopped when the 
bromophenol blue mark line came close to the edge of the gel. 
Coomassie Blue staining 
Gel was immersed in a staining solution of Coomassie Brilliant Blue R250 
(0.05% (w/v) for 1 hour. The gel was destained by immersing in the destaining solution, 
containing acetic acid:methanol:distilled water, (1:3:10，v/v/v). with frequent change of 
destaining solution, until the background became clear. A Pharmacia electrophoresis 
calibration kit, composed of phosphorylase b (MW 94,000), bovine serum albumin (MW 
66,000), ovalbumin (MW 43,000), carbonic anhydrase (MW 30,000), soybean trypsin 
inhibitor (MW 20,100) and a-lactalbumin (MW 14,400)，was used as molecular weight 
markers. 
2.5.2 Inhibition of calmodulin activation of cyclic nuleotide phosphodiesterase 
Activity was assayed by adopting an established protocol (Teo et al., 1973). 
Incubation mixtures contained, in a final volume of 1.0 ml, 40 mM imidazole, 2.5 mM 
CaCl2, 5 mM MgCl2, 0.2 unit of 5'-nucleotidase, 0.01 unit of cyclic nucleotide 
phosphodiesterase, and 10 units of calmodulin, in 40 mM Tris-HCl buffer, pH 7.5. Test 
compounds were added as solutions in ethanol (10 pi) to give a final concentration 
ranging from 0-100 pM. Reaction was started by addition of cyclic AMP (cAMP) to 
yield a final concentration of 1 mM. Incubation was run at 30^C for 30 minutes before 
1.0 ml of trichloroacetic acid (TCA) was added to precipitate protein. Control 
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incubations contained no cAMP. Calmodulin-independent activity was determined in 
incubations in which calmodulin was omitted. The inorganic phosphate obtained from 
Ihe supernate of centrifuged reaction mixture was determined according to inelhod of 
Ames (1966). Briefly, the supernate (0.3 ml) was added to 0.7 nil of reaction mixture 
containing 1 part of 10% ascorbic acid and 6 parts of 0.42% ammonium 
molybdate.4H20 in 0.5 M sulphuric acid. Incubation was run at 45^C for 20 minutes. 
Distilled water acted as blank and resulting absorbance at 820 nm was measured. 
2.6 Preparation of Pre-YCK, crude-YCK and post-YCK fractions 
This preparation actually borrowed most of the synthetic strategy from that of 
YCK. The synthesis of YCK starts with indole-3-carboxyaldehyde (Scheme 1，Cheng et 
al” 1985). Indole-3-carboxyaldehyde was protected as the N-p-toluenesulphonyl 
derivative. It was then treated with Grignard reagent derived from 3-chloro-2-
methylprop-l-ene and finally yielded the alcohol after appropriate purification. This 
alcohol was deprotected and dehydrated in one step to produce the MBDI. 
Acid condensation of MBDI (3.5 g) in silica gel/benzene system yielded crude 
YCK (3 g). Fractionation of crude YCK using flash column chromatography eluted with 
PE/E (petroleum ether: diethylether 7:3) collected 3 separate fractions and monitored 
using YCK as standard in TLC plate. Fraction 1 (60.4 mg/g) collected before elution of 
YCK. Fraction 2 contained crude-YCK (102 mg/g) and fraction 3 (148 mg/g) collected 
after elution of YCK. Both fraction 1 and 3 contained minor quantities of YCK. 
Fraction 1 was further purified using normal phase lobar column (petroleum 
etheridiethylether 7:3) yielded (26.3 mg/g) and named as pre-YCK; it was devoid of 
YCK. Fraction 3 was also further purified using reversed phase lobar column 
(methanol:water 8:2) yielded fraction (13.6 mg/g) and named as post-YCK. Therefore, 
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pre-YCK, crude-YCK, purified crude-YCK and post-YCK were then subjected to 
bioassay. The flowchart in next page schematically showed the whole process. 
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# 
MBDI (3.5 g) 
i 
Crude YCK (3 g) 
Flash Column Chromatography 
yr ^r T 
1 1 ” 
Fraction 1 (60.4 mg/g) Fraction 3 (148 mg/g) 
PE/E (7:3) Me0H/H20 (8:2) 
Lobar Si60 Lobar C18 
jr • 
Pre-YCK (26.3 Post-YCK 
mg/g) (13.6 mg/g) 
An outline of the preparation of pre-YCK, post-YCK and purified ‘crude-
YCK’ 
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H TS Ts { J y ^ 
q A J 
rt. H , 'V I 
H 
Scheme 1. Reagents: i, NaH, TsCI, W ; ii. CH2 = CMeCHgMgCI, THF： ill, 3N KOH/ EtOH; iv. CF3COOH. 
silica gel, benzene, 60OC. (Cheng et al., 1985) 
V 
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2.7 Preparation of Indole-3-carbinol acid condensation product (I3Ca) 
100 mg of indole-3-carbinol (Sigma) was dissolved in 2 ml DMSO and added 
dropwise into 100 ml of 0.05 M HCl (pH 1.3) slowly over 25 minutes with vigorous 
stirring. Following the acidification, the reaction mixture was extracted twice with 100 
ml aliquot of dichloromethane. The dichloromethane extract was evaporated and the 
resulting product redissolved in DMSO. This solution was stored at -20®C. This method 
was basically the same as that given by Bradfield and Bjeldanes in 1987. 
2.8 Studies on TCP series of YCK analogues 
Result from structure activity relationship of YCK analogues showed that YCK is 
a fairly conservative molecule. It would not allow any modification of the parent 
molecular structure without loss of biological activity, with the only exception that the 
saturation of the C9-C10 double bond resulted in an equipotent analogue in all model of 
bioassay. This prompts the idea of making a diminished YCK analogue with the 
elimination of the C9-C10 fragment. The synthetic approach to this diminished YCK, 
which is quite different from the condensation of 2 isoprenyl-indole precursors, afforded 
a selective hydroxylation of either one, or both, of the benzene ring at the C-3 position of 
YCK. Since this position is equivalent to the C-3 or C-2，positions in estradiol in which 
the 3-hydroxy position is essential for estrogen receptor binding. It is speculated that a 6-
OH-TCP-YCK would manifest enhanced estrogen receptor binding and cause much 
improved biological activity. Whether the estrogenic mode or anti-estrogenic mode of 
activity is affected remains to be seen. 
The synthesis of TCP-type YCK analogues was completed (Cheng et al., 1994; 
Scheme 2) and 6-OH-TCP and its methoxy derivative were made in-house. The 
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synthetic scheme was briefly outlined as follows: 
6 
, ' . ‘ _ . . . < (9) R = H 
4. ^ / \ / \ (10) R = 〇H 
(11) R = OMe 
7. H • 
Chiral centre 
2 - tert - Buty l - 3 - (indo卜3丨-yl) -1,2,3,4 - tet rahydrocyclopent [b] indole (TCP) 
, > 
Structures of TCP, 6-OH-TCP and 6-MeO-TCP 
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YCK TCP 
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O OH 
(6) 仍 
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O-i w 
(8) (9) 
Scheme 2 Synthetic Scheme of TCP (Cheng et al., 1994) 
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2.9 List of test compounds 







hexahydroindeno[2,1 - 口 
b] indole f ^ ^ Y i 
H 







methyl-6a6,7,8,10a6- „ J 
tetrahydroindeno[2,l- -ve (40.0) 
b]indole " /V 
m 
H 
2,5，-dimethyl-YCK 6B-(5，-methy l-Indol-3，- ^ 





N-1，,N-5-dimethyl- 66-(N-1 ’ -methy 1-Indol-
YCK 3’-yl)-7oc，7B，9- . 人 
aB- ：；：^  





















carboxyaldehyde V - / ^ -ve (100.0) 
genistein 4',5,7- ^ ^ / � “ 
trihydroxyisoflavone T | I p j 
J O V ^ -ve(12.5) 
+ve denoted positive result in anti-implantation 
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2.10 List of radio-ligands 
Systemic name and Specific activity Supplier 
position of labeling 
[2-^H(N)]-estradiol 20 Ci/mmol New England Nuclear 
(NET-822) 
[N-methyl-^H]-tamoxifen 82.5 Ci/mmol Amersham (TRK.748) 
[methyl-^H]-thymidine 5 Ci/mmol Amersham (TRA. 120) 
[2,4,6,7-^H]-estradiol 102 Ci/mmol Amersham (TRK.322) 
L-[l-14c]-ornithine 50-60 mCi/mmol Amersham (CFA.423) 
hydrochloride 
5，廿32p]_adenosine 3000 Ci/mmol Amersham (PB. 168) 
triphosphate 
[1 B-^H(N)]-androst-4-ene- 24.1 Ci/mmol New England Nuclear 
3,17-dione, (NET-926) 
[17a-methyl-^H]- 86.0 Ci/mmol New England Nuclear 
promegestone (R5020) (NET-555) 
[32p]-phosphoric acid 200 mCi/mmol Amersham (PB.4) 
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2.11 Miscellaneous reagents related to cell culture 
2.11.1 Culture medium 
RPMI-1640 powder (supplemented with 25 mM HEPES) was purchased from 
Sigma Chemical Company. The powder was dissolved in 1 litre of double distilled 
water, and the solution was supplemented with 2 g of NaHCOa and adjusted to pH 7.2-
7.4. Sterilisation was done by filtering through Millipore membrane with pore size of 
0.22 |im. 
2.11.2 Fetal calf serum 
Fetal calf serum was obtained from Gibco (U.S.A.) and was stored at -20°C in 50-
ml aliquot until use. Serum must be stripped free of steroid factors prior to adding to 
medium to give a final concentration of 5% (v/v). The stripping procedure had been 
mentioned in section 2.2.1.1.4. 
2.11.3 Penicillin-streptomycin powder 
Each vial of penicillin-streptomycin powder (Gibco, catalogue no. 600-5154AE) 
was reconstituted with 20 ml of double distilled water. Each vial was used to prepare 2 
litres of medium with final concentration of penicillin G at 10000 U/ml and 
• ‘ 
streptosmycin sulphate at 10000 |ig/ml respectively. 
2.11.4 Phosphate-buffer-saline (PBS) 
PBS was prepared by dissolving 8.0 g of NaCl, 0.2 g of KCl, 1.15 g of NaaHPO* 
and 0.2 g of KH2PO4 in 1000 ml double-distilled water. The solution was sterilised by 
autoclaving at 121�C for 30 minutes. 
2.12 Solvents, chemicals and scintillants 
Tamoxifen, progesterone, ornithine, 7-ethoxylresorufin, resorufin, indole-3-
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carbinol (I3C), 17-ethylyl-estradiol, POPOP, PPO, activated charcoal (Norit A) were all 
obtained from Sigma Chemical. Organic solvents were bought from E. Merck. 
Scintillant was prepared by dissolving dimethyl-1,4-bis-(2-(5-phenyloxazol))-
benzene (POPOP) (0.04%, w/v, final concentration)，2,5-diphenyloxazole (PPO) (0.4%, 




3.1 Rat uterotrophic response with EE2 and YCK 
A typical uterotrophic response in rats is shown in Table 1. Under maximal 
EE2 stimulation (0.03 mg/kg), uterine hypertrophy could reach 7.7-fold over control. 
YCK at 1 mg/kg, which is sufficient to prevent implantation, could only increase 
uterine weight by 4.9-fold over control. But co-administration of the two together 
stimulated only a 6.4-fold increase in uterine weight, i.e., significantly below (p<0.05) 
the degree of response by the same dose of EE2 alone. A similar pattern of attenuated 
response was observed in ODC activity {vide infra). 
Uterotrophic response began with EE2 at 1 ng/kg. The dose response curve 
rose linearly to 10 mg/kg and eased into a plateau at 30 mg/kg. In the presence of 
increasing doses of YCK, a mixed agonist/antagonist type of dose response curve was 
observed. At low EE2 (1 ^g/kg), YCK was estrogenic and contributed to the increase 
in uterine weight. The dose ratio of YCK (1 mg/kg) to EE2 (1 昭/ k g ) was 1000. At 
high dose of EE2, the stimulating activity of YCK was not manifest. On the contrary, 
it attenuated the full uterotrophic response of EE2 to a level below that attainable by 
the action of EE2 only. The inhibitory activity of YCK became apparent beyond 3 
|ig/kg EE2. At this dose point, YCK at a molar ratio of 300 in excess of EE2 did not 
contribute to any increase in uterine weight over EE2 action (Fig. 1) 
It was also noted that whereas YCK showed dose dependent uterotrophic 
response at low dose of EE2 (1 |ig/kg), the degree of inhibition was more or less the 
same for different doses of YCK when EE2 level was high (10 or 30 Mg/kg). At these 
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Concentration of EE2 (|jg/Kg) 
Fig. 1. Uterotrophic response of ethynyl-estradiol (EE2) in the 
presence of yuehchukene (YCK) in ovariectomised rats. Test 
compounds were administered by oral route. 〇，ethynyl-
estradiol only; A , ethynyl-estradiol with yuehchukene (0.03 
mg/kg); •，ethynyl-estradiol with yuehchukene, (0.1 mg/kg); 
•，ethynyl-estradiol with yuehchukene (1.0 mg/kg). Results 
are mean of 5 closely agreed values with control arbi trar i ly 
set to 1. 
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The difference between uterine weight with and without fluid was much more 
significant in the EE2-treated group, indicating that while YCK was uterotrophic, it did 
not increase uterine imbibition to the same extent as a classical estrogen. By comparing 
the amount of uterine fluid in different groups of EE2 plus YCK combination doses, it 
was noted that only at the highest level of EE2 (30 pg/kg), where fluid volume was 
maximum (78% of uterine weight) that the highest dose of YCK (1 mg/kg) could 
inhibit uterine imbibition (42% of uterine weight) to a significant extent. 
Microscopic examination revealed that both EE2 and YCK stimulated the 
hypertrophy of the myometrium There was no significant difference in uterine 
epithelial cell height in both experimental groups. Whereas in the control group, 
epithelial cells were obviously flattened (Fig. 2). 
3.2 Mice vaginal cornification with estradiol (E2) and YCK 
A similar pattern of mixed agonist/antagonist response was observed in mice 
vaginal smear. Epithelium cornification was detectable in 5% of animals treated at an 
intravaginal dose of 5 pg of estradiol; it rose linearly to 100% positive smears at a dose 
of 500 pg estradiol. When estradiol dose response curve was performed with 
increasing doses of YCK, it was superimposable with YCK at 5 ng. Stimulatory effect 
of YCK only was detectable at 50 ng, but this level of YCK could reduce maximal 
estradiol response from 100% to 70%. At 500 ng YCK, which showed fairly 
significant stimulatory effect with 35% positive smears, the combined dose of estradiol 
plus YCK produced almost the same effect (30%). Again inhibitory activity of YCK 
became apparent at an inflexion point when estradiol dosage was more than 15 pg 
(Fig. 3). 
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§ 1 1 … “ > … 
Fig.2 Histology of immature and ovariectomised rat uteri: after treatment 
with EE2 (a), YCK (b) and vehicle control (c). Tissues were fixed in 
alcoholic Bouin's fixative and sectioned at 10 micron, using hematoxylin-
eosin stain. 
Histological preparation were kindly assisted by Mr. K. S. Lee, director of 
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Estradiol daily dose (pg) 
Fig. 3. Percentage of animals wi th cornified vaginal epithelium by 
intravaginal administration of daily dose of test compounds as 
indicated. O，Estradiol only; •，estradiol wi th yuehchukene 
(5 ng); A , estradiol with yuehchukene (50 ng); •，est rad io l 
wi th yuehchukene (500 ng). Results are shown as percent 
positive scores f rom 10 animals. 
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3.3 Human breast cancer cell culture 
The growth response of 2 human breast cancer cell lines employed in this 
study, viz, MCF-7 and MDA-MB-231, were quantitated by tritiated thymidine 
incorporation, DNA measurement by fluorescent dye H33258 and cell count using 
Trypan Blue dye exclusion with haemocytometer. All 3 parameters exhibit a similar 
pattern of change. Therefore, in some experiment, DNA measurement was used 
instead of cell count for more accuracy. 
The estrogen receptor status of all cell lines were checked routinely to ensure 
the estrogen sensitivity and responsiveness. EIA-based methods was employed to 
monitor the estrogen receptor content (Fig 4a, 4b), indicating the specificity of the 
estradiol induced growth response. All experiments were performed under validated 
estrogen sensitivity and optimal cell growth conditions. 
3.3.1 MCF-7 cell growth with YCK 
MCF-7 is an estrogen responsive cell line (Soule et al., 1973) and it contains 
estrogen receptor (Fig. 4a). Hence, its growth required the presence of estradiol on top 
of optimal culture conditions. This cell line, which is maintained in charcoal stripped 
serum started to respond to estradiol stimulation at 1 pM by an increase in DNA 
content, it reached a maximum value at 1 nM (Fig. 5). Growth of MCF-7 cells 
maintained in stripped serum medium responded to estradiol treatment (0.1 nM) by an 
increase in cell number and DNA content. A similar degree of response was obtained 
with YCK at 0.01 pM. But in this bioassay model, YCK showed a reversed dose 
response curve, such that at 1 ^M, YCK produced no net increase in cell number over 
control (Fig. 6). 
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(R) 
Fig. 4a. Standard curve of ABBOTT ER-EIA Monoclonal • The linear plot 
was constructed from standard ( • ) provided according to 
procedures described in Methods and Materials. Protein content of 
the estrogen dependent cell line, MCF-7 cytosolic estrogen receptor 
preparation ( 〇 ) a n d nuclear estrogen receptor preparation ( A ) 
were adjusted to 1.5 mg/ml. Human control with 67 fmol/ml, was 
used as internal standard to estimate the validity of result. The 
amount of estrogen receptor in all three samples were read from 
standard curve, namely, 72 fmol/ml for human control (data not 
shown); 118 fmol/ml (79 fmol/mg cytosol protein) for cytosolic 
preparation; and 295 fmol/ml (197 fmol/mg cytosol protein) 
respectively. This clearly confirmed the presence of estrogen 
receptor in this estrogen dependent human breast cancer cell line. 
Note: specimens with values > 15 fmol estrogen receptor per mg cytosol protein are 
considered estrogen receptor positive and all samples have been diluted 2 folded as 
mentioned in Materials and Methods. 
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Fig. 4b. Standard curve of ABBOTT ER-EIA Monoclonal • The linear plot 
was constructed f rom standard ( • ) provided according to 
procedures described in Methods and Materials. Protein content of 
MDA-MB-231 cytosolic estrogen receptor preparation ( • ) was 
adjusted to 1.5 mg/ml and human control ( A ) , with 67 fmol/ml, was 
used as internal standard to estimate the validity of result. The 
amount of estrogen receptore in human control and MDA-MB-231 
were read f rom standard cuvre，namely, 72 fmol/ml and non-
detectable respectively. 
Note: All samples were diluted 2 folded as mentioned In the Materials and Methods and thus 
all readings from samples were half of the actual ones. 
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Fig. 5. Growth response of MCF-7 cells to various concentration of 
estradiol. MCF-7 cells were deprived of estrogen. Approximately 
5x10^ cells were plated into 25-cm2 culture flask. Cells were 
harvested after 5 days of treatment with estradiol as mentioned in 
Materials and Methods. Cellular DNA content was quantitated by 
fluorescent dye H33258 and read from a standard curve constructed 
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Fig. 6. Growth response of MCF-7 cells to estradiol or yuehchukene. 
MCF-7 cells were deprived of estrogen. Approximately 
cells were plated into 25-cm2 culture flask. Cells were harvested 
. ‘ 
after 5 days of treatment with test compound as mentioned in 
Materials and Methods. Cell number was estimated by 
haemocytometer. Results are expressed as mean ± S.D. f rom 
triplicate flasks. YCK=yuehchukene; E2=estradioL 
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Fig. 7. Growth response of MCF-7 cells to estradiol and yuehchukene. 
MCF-7 cells were deprived of estrogen. Approximately 5x10^ 
cells were plated into ZS-cm^ culture flask. Cells were 
harvested after 5 days of treatment with test compound as 
mentioned in Materials and Methods. Cell number was 
estimated by haemocytometer and represented by open bar. 
DNA content was quantitated by fluorescent dye H33258 with 
thymus DNA as standard and represented by striped bar. 
Results are expressed as mean ± S.D. f rom triplicate flasks. 
YCK=yuehchukene; E2=estradiol. 
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Microscopic examination using vital staining showed that the reversed dose 
relationship by YCK was not due to cytolysis until a concentration reaching 3-10 pM. 
. I 
Under these conditions of incubation, tamoxifen at 1 |jM inhibited cell growth to 
below the control level, whereas estradiol at 1 ^M caused cell death by cytolysis. 
In experiments where both estradiol (1 nM) could stimulate cell growth 
maximally and the net growth stimulated by YCK at 1 |iM became marginal, the co-
administration of the two at these concentrations could attenuate the level of cell 
growth to a level close to that induced by YCK alone. The increase in cell number was 
accompanied by corresponding changes in DNA content (Fig. 7). 
3.3.2 MCF-7 cell growth with YCK analogues and other related compounds 
In general, only those analogues with demonstrable estrogen receptor affinity as 
well as anti-implantation activity, i.e., they were estrogenic, could support the growth 
of MCF-7 cells. Thus, 9，10 dihydro-YCK could stimulate growth of MCF-7 cells and 
showed similar attenuating action in the presence of estradiol (Fig. 8). It was reported 
that this analogue carried equipotent activity in anti-implantation assay and in the 
present study, similar binding affinity towards estrogen receptor was observed {vide 
infra). 
Bis-nor-YCK was inactive in anti-implantation assay, but it demonstrated the 
reversed dose relationship as that of YCK in MCF-7 cell culture (Fig. 9a). It could 
also attenuate estrogen stimulated cell growth when the two drugs were administered 
together (Fig. 9b). Bis-nor-YCK showed binding to progesterone receptor though 
compared to 9,10 dihydro-YCK, it showed lower RBA to estrogen receptor {vide 
infra). 
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Fig. 8. Growth response of MCF-7 cells to 9,10-dihydro-yuehchukene 
and estradiol. MCF-7 cells were deprived of estrogen. 
Approximately 5x10^ cells were plated into 25-cm2 culture 
flask. Cells were harvested after 5 days of treatment wi th test 
compound as mentioned in Materials and Methods. Cell 
number was estimated by haemocytometer. Results are 
expressed as mean 士 S.D. f rom triplicate flasks. 9，10diH-
YCK=9,10-dihydro-yuehchukene, E2=estradiol; 
TAM=tamoxifen，a + b = l |iiM 9，10diH-YCK + 0.1 n M E2. 
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Fig. 9a. Growth response of MCF-7 cells to bis-nor-yuehchukene and 
estradiol. MCF-7 cells were deprived of estrogen. 
Approximately 5x10^ cells were plated into 25-cm2 culture 
flask. Cells were harvested after 5 days of treatment with test 
compound as mentioned in Materials and Methods. Cell 
number was estimated by haemocytometer. Results are 
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Fig. 9b. Growth response of MCF-7 cells to bis-nor-yuehchukene and 
estradiol. MCF-7 cells were deprived of estrogen. 
Approximately 5x10^ cells were plated into IS-cnfi culture 
flask. Cells were harvested after 5 days of treatment wi th test 
compound as mentioned in Materials and Methods. Cell 
number was estimated by haemocytometer. Results are 




2,5Mimethyl-YCK per se had no effect on the growth rate of MCF-7 cells. But 
when administered together with estradiol, there was a marginal attenuation in cell 
growth (Fig. 10). This might just reflect its diminished but demonstrable binding 
affinity towards both estrogen receptor or progesterone receptor {vide infra). 
As for inverto-YCK (Fig. 11)，N,N'-dimethyl-YCK (Fig. 12) and biskatole 
(Fig. 13)，they were all inactive even up to 1 |jM. In the presence of 0.1 nM estradiol 
which was active in supporting MCF-7 cell growth, these analogues could not 
attenuate cell growth even when dosed at 1 ^ iM. The drop in cell number observed for 
10 liM N，N，-dimethyl-YCK might probably be due to cytolysis phenomena (Fig. 12). 
Genistein, a kind of phytoestrogen with weak RBA of 1/100 to 1/75 to estrogen 
receptor (Shutt and Cox, 1972)，could promote the growth response of MCF-7 cell. At 
1 jjM of genistein, the extent of growth stimulation was close to that induced by 0.1 
nM of estradiol. Combined action of genistein at 1 pM and estradiol at 0.1 nM (dose 
ratio 1:10,000) gave a cell response equivalent to that of genistein only (Fig. 14). This 
result suggests that the stimulatory action of weak estrogens in MCF-7 growth does not 
necessarily lead to attenuation which is inherent in YCK structure. 
Indole-3-carbinol, obtained from cruciferous vegetables and known to be a 
potential anti-tumour agent (Wattenberg and Loub, 1978; Wattenberg, 1983; 
Dashwood et al., 1989)，could suppress MCF-7 cell growth (Tiwari et al., 1994) which 
was also observed in our system. However, this inhibitory effect required a longer 
incubation period in order to become apparent (Fig. 15) 
Due to the slow growth rate of MCF-7 cells, sample size was limited in each 
experiment. This was further complicated by a variable estrogen sensitivity, making 
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Fig. 10. Growth response of MCF-7 cells to tamoxifen, estradiol and 
2,5'dimethyl-yuehchukene. MCF-7 cells were deprived of 
estrogen. Approximately 5x10^ cells were plated into IS-cm^ 
culture flask. Cells were harvested after 5 days of treatment 
with test compound as mentioned in Materials and Methods. 
Cell number was estimated by haemocytometer. Results are 
expressed as mean 士 SJX from triplicate flasks. 
2,5'diMeY=2,5'-dimethyl-yuehchukene; E2=estradiol, 
TAM=tamoxifen, a + b = l n M 2,5'diMeY + 0.1 n M E2. 
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Fig. 11. Growth response of MCF-7 cells to estradiol and inverto-
yuehchukene. MCF-7 cells were deprived of estrogen. 
Approximately 5x10^ cells were plated into 25-cm2 culture 
flask. Cells were harvested after 5 days of treatment with 
test compound as mentioned in Materials and Methods. 
Cell number was estimated by haemocytometer. Results 
are expressed as mean ± S.D. f rom triplicate flasks. 
inverto-Y=inverto-yuehchukene; E2=estradioL 
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Fig. 12. Growth response of MCF-7 cells to N,N'dimethyl-dihydro-
yuehchukene. MCF-7 cells were deprived of estrogen. 
Approximately 5x10^ cells were plated into 25-cm2 culture 
flask. Cells were harvested after 5 days of treatment wi th test 
compound as mentioned in Materials and Methods. Cell 
number was estimated by haemocytometer. Results are 
expressed as mean 士 S.D. f rom triplicate flasks. N，N，diMe-
YCK=N,N'-diinethyl-yuehchukene. 
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Fig. 13. Growth response of MCF-7 cells to estradiol and biskatole. 
MCF-7 cells were deprived of estrogen. Approximately 
5x104 cells were plated into 25-cnfi culture flask. Cells 
were harvested after 5 days of treatment wi th test 
compound as mentioned in Materials and Methods. Cell 
number was estimated by haemocytometer. Results are 
expressed as mean 土 S.D. f rom triplicate flasks. 
Bsk=biskatole; E2=estradiol. 
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Fig. 14. Growth response of MCF-7 cells to tamoxifen, estradiol 
and genistein. MCF-7 cells were deprived of estrogen. 
Approximately 5x10^ cells were plated into 25-cm2 
culture flask. Cells were harvested after 5 days of 
treatment with test compound as mentioned in Materials 
and Methods. Cell number was estimated by 
haemocytometer. Results are expressed as mean ± S.D. 
f rom triplicate flasks. G=genistein; E2=0.1 n M estradiol, 
TAM=tamoxifen. 
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Fig. 15. Growth response of MCF-7 cells to indole-3-carbinol and 
yuehchukene. MCF-7 cells were deprived of estrogen. 
Approximately 1x10^ cells were plated into 75-cm2 culture 
flask. Cells were harvested after 8 days of treatment wi th 
test compound as mentioned in Materials and Methods. 
Cell number was estimated by haemocytometer. Results 
are expressed as mean ± S.D. f rom triplicate flasks. 
I3C=indole-3-carbinol; YCK=yuehchukene. In i t ia l seed 
represented the cell numbers seeded at day-1. 
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cross reference between two sets of experiments impracticable. Thus no attempt was 
made to run dose response curves of estradiol in the presence of different 
concentrations of YCK as in the two previous bioassay models. For the same reason, 
the minimal effective dose of YCK was not determined as sub-optimal concentration 
of YCK at the lower end of the dose range could not attenuate estradiol-induced 
growth response. In this regard, this represents the stimulatory mode of YCK action in 
MCF-7 cells and the inflexion point in this case should be 0.01 - 0.1 \xM YCK at 
minimal estradiol concentration ( l O . � - 1 0 ' ' M). 
3.3.3 MDA-MB-231 cell growth 
The estrogen independent cell line，MDA-MB-231，bearing no estrogen 
receptor (Fig. 4b), grew steadily in the presence of non-stripped serum and phenol red. 
Estradiol (at 0.1 nM) could not affect the growth rate of this cell line. While YCK 
administered in nano-molar range supports the growth of MCF-7 cell (1 nM - 100 nM), 
it was ineffective in stimulating cell proliferation over control in MDA-MB-231 cells 
(Fig. 17). This observation confirmed that the stimulatory action of YCK on MCF-7 
cell at optimal dose level was due to genomic activation of the ligand-estrogen receptor 
complex. Upon entering micromolar range, YCK began to show also cytolytic effect 
in this cell line (Fig. 16) 
3.4 Receptor Binding 
3.4.1 Rat uterine estrogen receptor 
YCK binds competitively to rat uterine estrogen receptor as well as to estrogen 
receptor preparation from human breast cancer cell line, MCF-7, albeit at a fairly low 
relative binding affinity (RBA). YCK binds to estrogen receptor with RBA of 1/300. 
Thus in estrogen receptor preparations saturated with 3 nM of labeled estradiol, it 
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Fig. 16. Growth response of MDA-MB-231 cells to estradiol and 
yuehchukene. Approximately 3x11)4 were plated into 
25-cin2 culture flask. Cells were harvested after 5 days of 
treatment with test compound as mentioned in Materials 
and Methods. DNA content was quantitated by fluorescent 
dye H33258 with thymus DNA as standard. Results are 
expressed as mean ± S.D. f rom triplicate flasks. 
E2=estradiol; YCK=yuehchukene. Ini t ial seed represented 
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Fig. 17. Growth response of MDA-MB-231 cells to estradiol and 
yuehchukene. Approximately 5x10 *^ cells were plated into 25-
, ‘ 
cm2 culture flask. Cells were harvested after 5 days of 
treatment wi th test compound as mentioned in Materials and 
Methods. DNA content was quantitated by fluorescent dye 
H33258 with thymus DNA as standard. Results are expressed 
as mean 士 S.D. f rom triplicate flasks. YCK=yuehchukene. 
Ini t ia l seed represented the DNA content of the number of 
cells mentioned. 
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could be displaced completely by 10 |iM of YCK, while at 1 \iU of YCK, it gave a 
50% decrease in binding. Pre-treatment of uterine cytosol with YCK prior to the 
addition of labeled ligand did not change the binding kinetics inspite of a small loss 
(10-15%) in binding capacity, probably due to receptor aging (Fig. 18). This suggested 
that the weak relative binding affinity was not due to alternation of estrogen receptor 
conformation in the presence of YCK. 
3.4.2 Mice uterine and vaginal estrogen receptor 
When mice uterine and vaginal estrogen receptor preparations were saturated 
with 2 nM of labeled estradiol and challenged with increasing concentrations of YCK, 
50% decrease in binding was observed at YCK:estradiol ratios of 389 ± 51.9 and 336 土 
29.0 respectively. Because the similarity of the results from both tissues, uterine 
estrogen receptor was re-run with YCK in a more closely spaced concentration range 
of both estradiol and YCK to obtain a more accurate estimate of the relative binding 
affinity of YCK. The ratio of YCK:estradiol for 50% decrease in binding was thus 
found to be 143 土 2.09 (Table 2). It was not possible to calculate a true relative 
potency as the two compounds showed a statistically significant difference in the 
slopes of the displacement curves. This observation was strongly reminiscent of the 
different dose response curve slopes in rat uterotrophic assay. 
3.4.3 MCF-7 whole cell and cytosolic estrogen receptor 
When MCF-7 whole cell estrogen receptor binding was performed with a few 
YCK analogues of fundamental difference in structure, only YCK could effectively 
displace labeled estradiol binding by 50% at around 0.3 ^M. At 10 |jM YCK, 
complete displacement was observed (Fig. 19). 9,10-dihydro-YCK, which was 
equipotent with YCK in anti-implantation and MCF-7 cell growth activities could bind 
to MCF-7 whole cell estrogen receptor preparation with the same relative binding 
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Table 2 Comparison between estradiol and yuehchukene in 
competition for binding to the mouse uterine cytosol 
estradiol receptor 
E2 YCK 
Relative % binding Relative % binding 
concentration concentration 
0.5 82.4 100 71.7 
1.0 69.7 200 56.4 
2.0 47.1 400 42.0 
40 28.5 800 30.0 
8 . 0 1 7 . 8 1 6 0 0 2 1 . 0 
1 0 4 
‘ > 
120 — 
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Fig. 18. Immature female rats uteri cytosol was incubated at 4®C with 3 n M 
[^H]-estradiol wi th increasing concentration of yuehchukene ( • ) • 
Pretreatment of uteri cytosol with increasing concentrations of 
yuehchukene ( A ) before addition of 3 n M [^H]-estradiol was 
performed under the same conditions as described in Materials and 
Methods. Binding of [^H]-estradiol in samples，determined after 20 
hours of competition by removing unbound radioactive label by 
charcoal suspension, was plotted against the concentration of 
yuehchukene. 
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affinity as YCK. But YCK analogues that were inactive in rat anti-implantation assay 
and MCF-7 cell culture might bind with diminished relative binding affinity (e.g., 2.5'-
dimethyl-YCK) or not bind at all (e.g., N,N'-dimethyl-YCK and biskatole) to MCF-7 
whole cell estrogen receptor preparations (Fig. 19). 
Binding experiments performed with disrupted cell, i.e. the cytosolic estrogen 
receptor prepared from MCF-7 cells was found to give essentially the same results as 
in the whole cell system (Fig. 20a, 20b). It suggested that YCK did not undergo any 
structural change upon entering the cell and prior to receptor binding. This observation 
corroborated with results from YCK pretreated estrogen receptor from rat uterus. 
3.4.4 MCF-7 progesterone receptor 
Estradiol could induce the synthesis of progesterone receptor (Horwitz et al., 
1978; Katzenellenbogen, 1980). YCK could also bind competitively to MCF-7 cell 
cytosolic progesterone receptor. It required around 0.4 |liM to displace 0.4 nM of 
labeled R5020 from progesterone receptor by 50%. At 10 \iM YCK, complete 
displacement was observed (Fig. 21). Unlike estradiol to estrogen receptor, R5020 is a 
kind of progesterone analogue with higher affinity toward progesterone receptor than 
progesterone itself. The RBA of YCK was about 1/300 in competing with R5020, 
same as YCK to estrogen receptor. But it is noted that the progesterone receptor 
displacement curves are strikingly parallel and complete. 
YCK was again the most potent analogue in this regard. Basically, the relative 
binding affinity of various analogues gave a picture resembling those obtained in 
estrogen receptor binding study. However, one exception was bis-nor-YCK, which 
showed growth stimulation in MCF-7 cell but was inactive in anti-implantation assay, 
also showed lower affinity in estrogen receptor binding than 9,10-dihydro-YCK. The 
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Fig. 19. MCF-7 whole cell estrogen receptor binding. Confluent cells 
in 6-well plate were incubated with 1 n M [^Hlestradiol at 
370c in CO2 incubator for an hour in the presence or 
absence of test compounds. Results from inactive analogues, 
such as N,N'-dimethyI-yuehchukene, etc., were not shown 
here. X，estradiol; •，yuehchukene; O，9,10 dihydro-
yuehchukene; A , 2,5' dimethyl-yuehchukene. 
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Fig. 20a. MCF-7 cytosolic estrogen receptor binding. Confluent cells 
f rom 8 T-150 flasks (Corning) were harvested and 
homogenised before centrifuged at 105,000 g for 1 hour. 
Protein content of the resulting supernate was adjusted to 1.5 
mg/kg and then incubated with 1 n M [3H]-estradiol wi th 
varying amount of test compound at 4"C for 20 hours. Binding 
of [^H]-estradiol in samples, determined after removing the 
free ligand in competition by charcoal suspension, is plotted 
against the concentration of test compounds. Results f rom 
inactive analogues, such as N,N'-diinethyI-yuehchukene, etc” 
were not shown here. X，estradiol; •，yuehchukene; O , 9,10 
dihydro-yuehchukene; A, 2，5, dimethyl-yuehchukene. 
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Fig. 20b. MCF-7 cytosolic estrogen receptor binding. Confluent 
cells f rom 8 T-150 flasks (Corning) were harvested and 
homogenised before centrifuged at 105,000 g for 1 hour. 
Protein content of the resulting supernate was adjusted 
to 1.5 mg/kg and then incubated with 1 n M [ 3 h ] -
estradiol wi th varying amount of test compound at 4®C 
for 20 hours. Binding of [^H]-estradiol in samples, 
determined after removing the free ligand in competition 
by charcoal suspension, is plotted against the 
concentration of test compounds. 眷，estradiol; •， 
yuehchukene; •，bis-nor-yuehchukene. 
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Fig. 21. MCF-7 cytosolic progesterone receptor binding. Confluent cells 
f rom 8 T-150 flasks (Corning) were harvested and homogenised 
before centrifuged at 105,000 g for 1 hour. Protein content of 
the resulting supernate was adjusted to 1.5 mg/kg and then 
incubated with 0.4 n M [3H]-R5020 with varying amount of test 
compound at 4®C for 20 hours. Binding of [^H]-R5020 in 
samples, determined after removing the free ligand in 
competition by charcoal suspension, is plotted against the 
concentration of test compounds. •，yuehchukene; •，R5020. 
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order was reversed in the progesterone receptor binding affinity, (Fig. 22)，with a 
relative binding affinity about 1/300; it was even stronger than 9,10-dihydro-YCK in 
the displacement of R5020. 9,10 dihydro-YCK had a weaker relative binding affinity 
of around 1/500 in competing for R5020. 
3.4.5 Rat hepatic anti-estrogen binding sites (AEBS) 
A parallel experiment with anti-estrogen binding sites from rat liver showed 
that whereas tamoxifen could displace [^HJ-tamoxifen by 50% at 10 nM, YCK could 
not effectively displace the labeled ligand until 0.1 mM. A precipitous slope of the 
displacement curve indicated non-competitive binding (Fig. 23). 
3.5 Enzyme activities related to estrogen metabolism 
3.5.1 Rat uterine ornithine decarboxylase (ODC) 
It was observed that uterine ODC activity was parallel to the degree of uterine 
hypertrophy in ovariectomised rats according to their treatments. When ODC activity 
was assayed in ovariectomised immature rats dosed over 3 days, EE2 at 30 [ig/kg could 
stimulate a 4.9 fold increase in enzyme activity while it increased the uterine weight to 
7.7 fold over control. YCK alone, at 1 mg/kg was only marginal (55% over control) in 
enzyme induction but it could stimulate about 5 fold increase of uterine weight over 
control. The co-administration of these two together could attenuate the increase in 
ODC activity to only 2.4 fold over control (Table 1). This pattern of biological 
response was consistent with those observed in rat uterine hypertrophy, mouse vaginal 
epithelium cornification and MCF-7 cell growth. 
A parallel experiment compared YCK with indole-3-carbinol acid condensation 
products and found that where YCK at 1 mg/kg could stimulate a 2-fold increase in 
ODC activity, I3Ca was not active (Table 3). 
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Fig. 22. MCF-7 cytosolic progesterone receptor binding. Confluent cells 
f rom 8 T-150 flasks (Corning) were harvested and homogenised 
before centrifuged at 105,000 g for 1 hour. Protein content of the 
resulting supernate was adjusted to 1.5 mg/kg and then incubated 
wi th 1 n M [3H]-R5020 wi th varying amount of test compound at 
4®C for 20 hours. Binding of [^H]-R5020 in samples, determined 
after removing the free ligand in competition by charcoal 
suspension, is plotted against the concentration of test compounds. 
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Fig. 23. Ligand specificity of anti-estrogen binding sites of rat liver. [^H]-
tamoxifen was incubated with rat liver 20,000 g supernate in the 
presence of various amounts of tamoxifen ( • ) and yuehchukene ( • ) • 




Induction of ornithine decarboxylase activity in ovariectomised immature rats 
Control 100 ± 26.4 
YCK (1 mg/kg) 225 ±51.22 
I3Ca (166mg/kg) 70.05 土 27.69 
Each represented mean ± S.D. of 3 samples compared with control as 100. 
When ornithine decarboxylase (ODC) activity was assayed in immature intact 
rats dosed over 2 days, the degree of uterine hypertrophy due to YCK (1 mg/kg) had 
only increased by 2.2 fold over control. This was expected because intact rats were not 
deprived of endogenous estrogen. There was also a lesser increase in ODC activity 
(140-160%) which was nevertheless significantly above the control value. In the same 
experiment, I3Ca at 166 mg/kg or MBDI at 13.2 mg/kg were not uterotrophic at all. 
They could only marginally stimulate ODC activity but the results were not statistically 
significant due to a broad range standard deviation (Fig. 24). 
3.5.2 Rat hepatic estradiol-2-hydroxylase and ethoxyresorufin O-deethylase (EROD) 
In intact immature rats dosed over 2 days, I3Ca showed a prominent 
stimulation of a 300% increase in estradiol-2-hydroxylase activity whereas MBDI 
induced activity of the same enzyme was almost doubled. This pattern was followed 
closely by measuring concurrently EROD activities with the same microsomal 
preparation. Compared with these two active compounds, the stimulatory effect of 
YCK on estradiol-2-hydroxylase was only marginally above that of vehicle control and 
YCK did not stimulate EROD at all (Fig. 24). 
114 
Fig. 24. Induction of 2-hydroxylase, EROD and ODC activities; uterotrophic 
response in yuehchukene (YCK), methylbutadienylindole (MBDI)， 
indole-3-carbinol add condensation products (I3Ca)-treated intact, 
day 18 Sprague-Dawley rats injected by the p.o. route. Female rats 
were administered 2 doses daily for all test compounds and were 
killed 20 h after the last dose. For ornithine decarboxylase assay, 
each sample was pooled from tissues of 3 rats and each bar is the 
mean of two samples. For the other assays, liver microsomes were 
prepared from individual rats. In the utertrophic assay, the result is 
the mean for 6 rats ± S.D. IZZI, hepatic estradiol-2-hydroxylase;-
I 1; hepatic ethoxyresorufin O-deethylase activity; uterine 
ornithine decarboxylase activity; ISSI, uterotrophic activity. 
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In other experiments with intact immature rats, 1 mg/kg YCK dosed over 20 
hours and 48 hours could stimulate a small (6-10%) but statistically significant 
increase in hepatic estradiol-2-hydroxylase while I3Ca could stimulate twice as much 
(Fig. 25a). In this experiment, the EROD activity in the 48 hours group was measured. 
It was found that I3Ca could stimulate EROD activity by 100% and the stimulatory 
effect of YCK was noticeable but not statistically significant (Fig. 25b). Repeating this 
experiment (Fig. 26a,b) with immature rats ovariectomised at age day-18 and used one 
week later, hepatic estradiol-2-hydroxylase showed a dose dependent increase from a 
crude preparation of YCK at 13 mg/kg ( -50% over control) and 40 mg/kg ( -90% over 
control). The same samples were concurrently assayed for EROD activity, a similar 
dose dependent increase in enzyme activity was observed which was significant at 40 
mg/kg of YCK. These rats were also dosed for 2 days. 
When ovariectomised rats were fed with MBDI at 8，16，and 32 mg/kg for 3 
days，it exhibited dose dependent enhancement on hepatic EROD and estradiol-2-
hydroxylase (Fig. 27). MBDI, which is the immediate precursor of YCK, elicited 
much higher response in both enzyme assays compared to YCK. 
In order to pinpoint the active component accountable for enzyme induction, 
the full spectrum of MBDI acid condensation products was divided into 3 fractions, 
namely, pre-YCK; crude-YCK and post-YCK. These 3 fractions represented 3 groups 
of reaction mixtures with increasing degree of intermolecular condensation，in that 
order. The crude-YCK yielded the purified crude-YCK fraction by chromatographical 
elimination of non-YCK components. When ovarectomised rats were dosed at 40 
mg/kg for 3 days with each of the three fractions on a same weight basis, pre- and post-
YCK stimulated more or less the same degree of increase in hepatic estradiol-2-
hydroxylase activity (approximately 140% over control)whereas the crude-YCK was 
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Fig. 25a,b. Induction of hepatic estradiol-2-hydroxylase and EROD activity 
in I3Ca- or YCK-treated Sprague-Dawley rats. Female rats (18-
day old) were dosed twice per day p.o. 166 mg/kg of I3Ca or 1 
mg/kg of YCK, for 20 hours, (open bar) or 48 hours (striped 
bar). Hepatic microsomes were prepared and CYPlA-dependent 
EROD activity were assayed as described in the Materials and 
Methods. Results expressed as mean 土 S.D. (n=3-5). * indicates 
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Fig.27. Induction of hepatic estradiol-2-hydroxylase activity in 
methylbutadienylindole (MBDI) and yuehchukene (YCK) treated 
ovariectomised, day-18 Sprague-Dawley rats by p.o. route. Female 
rats were administered 2 doses daily for all test compounds and 
were sacrificed at 20 hours, after last dose. Result of the hepatic 
estradiol-2-hydroxylase was mean 土 S.D. 
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weaker (70% increase over control) (Fig. 28a). When the same microsomal samples 
were assayed for EROD assay, crude-YCK and post-YCK doubled the EROD activity 
while pre-YCK, stimulated only a 60% increase over control (Fig. 28b). The same 
kind of experiment on estradiol-2-hydroxylase was repeated after the crude-YCK 
fraction had been further purified. Interestingly, the purified crude-YCK (10 mg/kg) 
showed the highest potency in the stimulation of estradiol-2-hydroxylase activity 
among the three. With more than 3 fold increase over control. Such magnitude of 
stimulation was never observed with YCK, dosage notwithstanding. Pre-(10 mg/kg) 
and post-YCK (10 mg/kg), on the other hand, resulted in only doubling of enzyme 
activity (Fig. 29) 
Enterolactone itself could not induce estradiol-2-hydroxylase in ovariectomised 
rats Under the same experiment, I3Ca at 166 mg/kg showed prominent stimulation of 
estradiol-2-hydroxylase (Fig. 30). 
3.5.3 MCF-7 cell estradiol-2-hydroxylase 
Swaneck and Fishman (1991) reported estradiol-2-hydroxylase activity in 
MCF-7 cell. In our hands, it was hard to demonstrate a strong activity as the cell line 
had been kept in stripped serum over 1 year. When this experiment was performed, a 
weak but significant response could be observed, only after prolonged (1 week) 
exposure to the test compounds. 
MCF-7 cell estradiol-2-hydroxylase was stimulated by EE2 and YCK but 
attenuation by EE2 plus YCK on estradiol-2-hydroxylase was not evident due to a low 
level of activity. In this experiment, I3C was also inactive probably due to insufficient 





























































































































































































































































































































































































































1 3 0 -
i 2 5 - 丁 
i 2 0 - ~ ~ r ^ 
c 





0 " I I ~ ~ I ~ I ~ ~ I 
8 1 •§ 
% I ^ 
^ ^ o < 
q ^ 
Q . (D 
I •< o 
Fig. 29. Induction of hepatic estradiol-2-hydroxylase activity in 
in purified crude-YCK (lOmg/kg); pre-YCK (lOmg/kg) and 
post-YCK (lOmg/kg) treated ovariectomised, day-18 
Sprague-Dawley rats by p.o. route. Female rats were 
adminstered 2 doses daily and were sacrificed at 20 hours, 
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Fig. 30. Induction of hepatic 2-hydroxylase activity in yuehchukene (YCK), 
methylbutadienylindole (MBDI), indole-3-carbinol acid condensation 
products (I3Ca), enterolactone (enl)-treated ovariectomised, day-18 
Sprague-Dawley rats by p.o. route. Female rats were administered 2 
doses daily for all test compounds and were sacrificed at 20 hours after 
last dose. Result of the hepatic estradiol-2-hydroxylase was mean ± 
S.D. 
124 
400 I I 1 1 
5 3 5 0 - -
r— O 
•1— 1 
2 3 0 0 - -
！ (U 
1-1 
5 2 5 0 - -JC m 
1__I 
rvj g 200 - -
t H 
• S 1 5 0 - -
W) fd 0) 
^ 100 - -
o 
rvi IE m 
5 0 - -
ol ‘ ‘ ‘ 
cell Y C K I m M I 3 C 0 . 1 | j M 
. ‘ 
Fig. 31. Induction of hepatic estradiol-2-hydroxylase activity in MCF-7 cell 
by yuehchukene (YCK), indole-3-carbinol (I3C). Near confluent 
cells were pre-incubated with test compounds for 4-5 days and 
approximately 1x10^ cells were plated into 25-cm^ culture flask. 
Same treatment were continued for another 3 days. Detailed 
procedure was described in Methods and Materials. Each flask was 
received 1 j iCi of radiolabeled substrate and incubated for 24 hours. 
Result of the hepatic estradiol-2-hydroxylase was mean ± S.D. 
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3.5.4 Human placenta and MCF-7 aromatase 
YCK at 1 liM had no effect at all on aromatase activity which was assayed by 
the formation of tritiated water from aromatisation by using [ H]-androstenediol as 
substrate. From Fig. 32，the extent of aromatization of substrate was increased linearly 
with increasing concentrations of microsomal preparation. But the extent of 
aromatisation in the YCK (1 i^M) treated group is hardly different from the control 
group, whereas an aromatase inhibitor, aminoglutimide, at 10 jiM showed dramatic 
suppression of aromatase activity. This pilot experiment left little hope that variation 
in time dependence as well as the substrate concentration could yield more information 
on the kinetic properties of the aromatase under the influence of YCK. 
Using the same regioselectively labeled androstenedione, the effect of YCK on 
MCF-7 cell aromatase was examined. While YCK at 1 \iM had no effect at all, the 
addition of 10 |iM aminoglutethimide to the cell culture for 4 days was slightly 
cytotoxic. A combination of this sublethal dose of YCK (1 |iM) and same 
concentration of aminoglutethimide yielded the same outcome (Fig. 33)，suggesting 
that YCK could not reverse aromatase inhibition. 
3.6 Enzyme activities related to signal transduction 
3.6.1 Protein kinase C inhibition in vitro 
In vitro PKC inhibitory action of both YCK and TAM was compared and 
summarised in Fig. 34. Obviously, both had similar inhibitory action although YCK 
seemed to have a slightly higher potency. At around 14 i^M, YCK could suppress 50% 
of PKC activity. TAM needed to go up to 80-90 \iM to achieve the same level of 
inhibition under the present condition. However, the phosphorylation pattern from 
MCF-7 cells treated with either YCK or TAM did not show any significant difference 
from control (Fig. 37). 
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Fig. 32. Action of 10 yiM aminoglutethimide (AG, • ) or 1 iliM 
yuehchukene (YCK, • ) on human placental aromatase activity 
Control group ( • ) received ethanol vehicle only. Substrate was 
40 nM, [lB-^H(N)]-androst-4-ene-3,17-dione. 
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Fig. 33. Action of 10 |liM aminoglutethimide, 1 \xM yuehchukene and 1 p M of 
Y C K plus 10 |nM AG on human breast cancer cell line, MCF-7 
aromatase activity. Control group received ethanol vehicle only. 
Substrate was 40 nM, [lB-^H(N)]-androst-4-ene-3,17-dione. Result 
are expressed as mean ± S.D. 
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kinase C activity f rom MCF-7 cell cytosolic preparation. Test 
compounds were dissolved in ethanol and added at the f inal 
indicated concentration. Results are expressed as mean ± S.D. 
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Fig. 37. Effects of tamoxifen and Y C K on protein phosphorylation in intact 
MCF-7 cells. Subconfluent cells were incubated for 30 minutes in 
phosphate-free Krebs-Ringer buffer containing 50 j iCi of [^^P]-
phosphoric acid in the absence (Control) or in the presence of 10 |iiM 
tamoxifen (TAM) , 15 ^iM of yuehchukene (YCK). Test compounds 
were dissolved in ethanol and the final concentration of ethanol in 
medium never exceeded 0.2% (v/v). TCA-precipitated proteins were 
analysed by SDS-PAGE and autoradiography. This picture was 
captured by CCD camera and printed by video printer. 
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3.6.2 Camodulin-dependent phosphodiesterase inhibitory actions in vitro 
PDE activity was much increased in the presence of calmodulin, TAM exerted 
an inhibitory action only in the presence of calmodulin; in its absence, no inhibition 
was observed. With the presence of 10 units of calmodulin, about 10|liM of T A M 
could neutralise completely any increase in PDE due to the presence of calmodulin 
(Fig. 35). To achieve similar level of inhibition, YCK required more than 100 ^M 
(Fig. 36). I3C was not active at all. 
The source of protein kinase C was obtained from MCF-7 cells whereas the 
phosphodiesterase system was reconstituted in-vitro. Since these experiments were 
carried out in in-vitro system only, they were mainly designed to characterise the 
pharmacological action of which YCK might predispose. These results are included 
here for the purpose of broadening the perspective of YCK action mechanism. 
3.7 Studies on TCP series of YCK analogues 
The synthesis of TCP was published (Cheng et al., 1994; scheme 2) and 6-OH-
TCP and its methoxy derivative were made in-house. This series of TCP-analogues 
are thus tested for biological activity in a battery of bioassay models routinely carried 
out in this laboratory and the results are as follows: 
TCP was active in rat anti-implantation assay at a dose of 2.5 mg/kg. This is 
equipotent with YCK. But depending on purity, YCK could be active as low as 0.625-
1 25 mg/kg. TCP dosed at these levels were inactive. Thus as far as this bioassay 
model is concerned, TCP is 50% or at best approaching 100% as active as YCK (Table 
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2.5 mg/kg was active, so was EE2 at 0.1 mg/kg. TCP therefore carried less than 4% of 
relative estrogenic potency and its hydroxylated derivative was not more active as 
would be expected. 
In immature rat uterotrophic assay, where EE2 at an optimal dose of 0.03 
mg/kg could produce a 6.5-fold increase in uterine weight, an optimal dose of YCK at 
1 mg/kg could only reach 5.5 fold (or 85% of EE2 activity), TCP at three times of 
YCK dose was less active than YCK by stimulating only a 5-fold increase in uterine 
weight. This is 90% of YCK potency at this dose, and 30% of YCK potency at the 
same dose level. OH-TCP was still less active, it was only 94% of TCP potency at the 
same dose level (Table 6). 
, ‘ 
A 4-point dose response curve of OH-TCP showed that it was not active until 
1.0 mg/kg. A slow rising slope indicated that OH-TCP was not more active than YCK 
in uterotrophic assay (Table 7). 
Comparing with 6-OH-TCP, the methoxy derivative rose in a steeper slope in 
uterotrophic assay but reaching the same plateau value at 1.0 mg/kg (Table 8). 
TCP and its 6-OH derivative could induce ornithine decarboxylase (ODC) 
activity with a level comparable to YCK (1 mg/kg) at three times the dose level 
(3mg/kg). EE2 could induce the same degree of increase in enzyme activity at only 
0.03 mg/kg (Table 9，Table 10). While it seems that TCP and 6-OH-TCP were more 
potent in ODC induction than uterotrophic response, MeOH-TCP was less active than 
the two in ODC induction (Table 11). 
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TCP binds to rat uterine estrogen receptor at a weak RBA of 1/300 but in a near 
parallel displacement curve. 6-MeOH-TCP yielded similar results (data not shown). 
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Table 4 ： Anti-implantation activity of TCP in female rats. Vehicle control group had 
100% fertility. Each data represents the result from one group of animal 
containing 5 rats. 
Compound Dose No Preg./ Remarks 
(mg/kg, PDI-4) NO Tested 
TCP 0.625 ^ 
1.25 ^ - v e 
2.5 + ve 
5.0 +ve 
Vehicle Control 1 ml ^ _ ve 
Table 5 : Anti-implantation activity of 17a-ethynyl-estradiol, YCK, TCP and 6-OH-TCP 
in female rats. Vehicle control group had 100% fertility. Each data represents the 
result from one group of animal containing 5 rats. 
Compound Dose No Preg./ Remarks 
(mg/kg, PDI-4) No Tested 
17a-ethynyl estradiol 0.1 ^ 十^。 
TCP 竺 ^ +ve 
6-OH-TCP 0 3 ^ - v e 
6-OH-TCP 1 ^ - v e 
YCK 1 6/6 - ve 
Vehicle Control I n ^ _ ve 
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Table 6 ： Uterotrophic activity of 17a-ethynyl-estradiol (EE2), 6-hydroxy-TCP and 
Control in immature rats. Each group data is the mean of six closely agreed 
determination. 
Dose (mg/kg) Uterine weight/Body weight 
(mg/g) 
Control oil vehicle 0.151 ± 0.01 
n=6 
EE2 0.03 0.979 ±0.15 
n=6 
YCK 1.0 0.833 ±0.02 
n=6 
TCP 3.0 0.756 土 0.04 
n=6 
6-OH-TCP 3.0 0.712 ±0.07 
n=6 
Table 7 : Dose response curve of 17a-ethynylestradiol (EE2), 6-hydroxy-TCP and 
Control in uterotrophic activity in immature rats. Each group data is the mean of 
six closely agreed determination. ^ Data point at dose 3mg/kg was borrowed 
from Table 4 with adjustment and extended directly to 3mg/kg using 
EE2/Control ratio. 
Dose (mg/kg) Uterine weight/Bogy weight 
(mg/g) 
Control oil vehicle 0.164 ± 0.03 
n=6 
EE2 0.03 1.156 ±0.17 
n=6 
6-OH-TCP 0.1 0.154 ±0.(B 
n=6 
n=6 ^ 0.153 ±0.02 
n=6 1.0 0.351 ±0.09 
n=6 3 £ 0.774 ± 0.08 ^ 
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Table 8 ： Dose response curve of 17a-ethynylestradiol (EE2), 6-methoxy-TCP and 
Control in uterotrophic activity in immature rats. Each group data is the mean of 
six closely agreed determination. 
Dose (mg/kg) Uterine weight/Body weight 
(mg/g) 
Control oil vehicle 0.149 ±0.01 
n=6 
EE2 0.03 1.052 ±0.11 
n=6 
6-Meo-TCP 0.1 0.190 ±0.02 
n=6 
n=6 0.3 0.335 ± 0.04 
n=6 J ^ 0.787 ± 0.07 
n=6 0.644 ± 0.09 
Table 9 : Tested compounds were dosed orally twice daily for 3 days. Upon autopsy 24 
hours after the last dose, ornithine decarboxylase activity (ODC) per mg 
cytosol protein per hour was measured and expressed as the mean of two 
separated experiments. 
Compound Dose (mg/kg) %Control of ODC Activity /mg 
Cytosol Protein/hour 
1/ Control oil vehicle 100 ± 14.18 
n=6 
2/ EE2 0.03 150.65 ±4.17 
n=6 
3/ YCK 1.0 141.21 ±9.0 
n=6 
4/TCP “ 3.0 133.59 ±18.96 
n=6 
5/6-OH-TCP 3.0 129.27 ±0.52 
n=6 
138 
Table 10 ： Tested compounds were dosed orally twice daily for 3 days. Upon autopsy 24 
hours after the last dose, ornithine decarboxylase activity (ODC) per mg 
cytosol protein per hour was measured and expressed as the mean of two 
separated experiments. 
Compound Dose (mg/kg) %Control of ODC 
Activity /mg 
Cytosol Protein 
Control oil vehicle 100 土 9.26 
n=6 
EE2 0.03 166.96 ±16.34 
n=6 
6-OH-TCP 0.1 112.10 ±11.45 
n=6 
n=6 114.32 ±4.61 
n=6 1.0 I 153.66 ±29.0 
Table 11 : Tested compounds were dosed orally twice daily for 3 days. Upon autopsy 24 
hours after the last dose, ornithine decarboxylase activity (ODC) per mg 
cytosol protein per hour was measured and expressed as the mean of two 
separated experiments. 
Compound Dose (mg/kg) %Control of ODC Activity 
/mg Cytosol Protein 
Control oil vehicle 100 土 14.6 
n=6 ； 
EE2 0.03 468.20 ±173.7 
n=6 
6-MeO-TCP 0.1 168.82 ± 126.7 
n=6 
n二6 0.3 80.82 土 0.43 
n:=6 一 J ^ 124.60 ± 6.0 
n=6 125.49 ±7.5 
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4. Discussion 
YCK is the most potent compound discovered in a multidisciplinary 
international collaborative research programme in search of plant fertility agents (see 
W.H.O. monograph). Indeed, it is the most potent natural product estrogenic 
compound ever reported in literature. While it becomes clearer now that the anti-
implantation activity of YCK is probably attributable to its estrogenicity, the structure 
function relationship of this compound is not yet fully assessed. Most of these effort 
were hampered by the lack of monitoring systems to dissect the variety of structural 
elements involved. The work reported here mainly emphasises the functional role of 
YCK as a mixed estrogen/anti-estrogen, as conferred by the parent structure. This may 
help to orientate future structure activity relationship in an effort to exploit the anti-
estrogen effect of yuehchukene. 
4.1 Estrogenicity of YCK 
The estrogenicity of YCK could be clearly demonstrated at 4 different 
organismic level, viz. whole body—uterine hypertrophy, organ—vaginal epithelium 
cornification, cellular—MCF-7 cell growth and molecular—ODC induction. All these 
systems can be stimulated by estrogen or estrogenic compounds. In each case, YCK 
indeed exhibited stimulatory activity, albeit not to the same extent as estradiol. 
In all the bioassay models studied, YCK remained the most potent compound 
among all analogues tested. It suggests that YCK has a very conservative structure as 
far as estrogenic action is concerned. 
140 
4.2 Estrogenicity of YCK correlates with estrogen receptor (ER) binding 
Receptor binding studies (rat uterine, mice vaginal and uterine, MCF-7 cells) 
confirmed that YCK could bind to estrogen receptor although with a low binding 
affinity. Therefore, it is fair to conclude that estrogen receptor binding is correlated to 
the observed estrogenicity of YCK. In these in vitro binding studies, YCK 
demonstrated more or less the same RBA in rat uterine estrogen receptor (approx. 
1/150-1/300), mice uterine estrogen receptor (1/145), and MCF-7 cell (1/300). It is 
more likely than not that the estrogenicity of YCK was due to genomic activation of 
theYCK-ER complex. It should be noted that the binding of YCK to estrogen receptor 
involved no prior transformation in the part of YCK or the receptor, since the pre-
incubation of YCK with rat uterine estrogen receptor did not change the displacement 
curve and there is close resemblance of binding affinity between MCF-7 cytosolic 
estrogen receptor and whole cell estrogen receptor. There is a possibility that the 
biotransformation of YCK in liver could yield an active intermediate, thus explaining 
the high relative potency in anti-implantation from a compound with weak RBA in 
estrogen receptor binding. But results from OH-TCP did not support this hypothesis. 
This correlation was further corroborated by comparing the binding affinity of 
various YCK analogues to bioassay results. It suffices to say that analogues inactive in 
anti-implantation assay or in MCF-7 growth response does not bind (N，N，-dimethyl-
YCK; biskatole; inverto-YCK), or bind with much weaker affinity than YCK (2，5，-
dimethyl-YCK). Therefore, YCK remains the most potent compound among a long • ‘ 
list of structural analogues in which only YCK and dihydro-YCK could manifest 
estrogenic activity. 
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4.3 Attenuation by YCK on estrogen action 
4.3.1 Attenuation by YCK on estrogen induced uterotrophic activity 
The graphic presentation (Fig. 1) of results from uterotrophic assay did not 
conform to a competitive inhibitor or that of a non-competitive inhibitor. Hence, YCK 
produced what can be more appropriately described as a mixed agonist/antagonist type 
of dose response curve in which the stimulatory mode crossed over to the inhibitory 
mode at a fairly well defined inflexion point. The attenuation was noticeable beyond 3 
pg/kg EE2. YCK could attenuate the estrogenic action even at a dose ratio of only 30 
to 100 in excess of EE2. According to the results of binding studies, YCK, at this dose 
point could not completely displace estrogen from estrogen receptor. Furthermore, the 
lack of YCK dose dependence on this attenuation phenomenon when EE2 dose was 
beyond 10 pg/kg suggests that some other mechanisms may be involved that are 
outside the sphere of the estrogen receptor complex genomic action. 
In the absence of or at low dose of EE2(1 |ag/kg)，YCK showed a dose 
dependent uterotrophic response, indicating the instrinsic estrogenicity of YCK. At 
this dose point, YCK had a dose ratio of 1000 in excess of EE2. The estrogen receptor 
was most likely almost fully occupied by YCK. 
4.3.2 Attenuation by YCK on mice vaginal cornification with estradiol and YCK 
The graphic representation of results from vaginal cornification studies (Fig. 3) 
also demonstrated an attenuation induced by increasing amount of YCK. Just like the 
uterotrophic experiment, YCK elicited a dose dependent attenuation with an inflexion 
point at about 15 |ag/kg estradiol. Since EE2 was applied intravaginally’ it must be 
assumed that attenuation is due to the direct action of YCK on the target tissue. 
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4.3.3 Attenuation by YCK on MCF-7 cell growth 
In MCF-7 cell culture and induction of ornithine decarboxylase, an inflexion 
point had not been established but a bimodal response was distinguishable. The 
inhibitory mode was particularly noticeable in MCF-7 cells which required a minimal 
level of estradiol (10"'^ to 10] ^  M) to remain viable. Here YCK demonstrated a 
reversed dose response curve. This observation highlighted the fact that the 
antagonistic effect of YCK only became evident in the presence of an optimal 
concentration of estradiol, whether it was re-introduced to estrogen-deprived system 
(e.g., ovariectomised rat) or where it formed an integral part of the intracellular milieu 
(cell culture). 
The human breast cancer cell line MCF-7 is known to be estrogen dependent 
because of its growth and proliferation requires the presence of estrogen or other 
estrogenic compounds such as DES, or even phenol red (Berthois et al., 1986). This 
property has long been attributed to the presence of intracellular estrogen receptor in 
MCF-7 cells. Optimal concentration of estrogen is necessary but not sufficient to 
stimulate the proliferative response. Other factors, for instance, growth factors are also 
important (van der Burg, 1991). Hence, the MCF-7 cell line has become an 
established in vitro test system for the study of structure activity relationship of various 
anti-estrogens. It also provides a handy source of human estrogen receptor preparation 
that can also be employed to correlate the RBA of different ligands with the extent of 
estrogenicity in terms of their cell proliferation capability. 
In the present study, most of the YCK analogues, including N’N' dimethyl-
YCK, 2,5'-dimethyl-YCK, biskatole, inverto-YCK, could not show any effect on the 
growth of MCF-7 cell. YCK, in a reversed dose relationship, stimulated the growth of 
MCF-7 cells from 0.1 nM to 100 nM range; whereas it could inhibit the growth of 
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MCF-7 cells at concentration at or larger than 1 i^M. However, the growth inhibitory 
effect is particularly noticeable in the presence of an optimal amount of estrogen. 
The bimodal response demonstrated in both uterotrophic assay and cell culture 
system strongly suggested that YCK at high doses may activate other pathway to 
attenuate estrogen action than the simple replacement of estradiol from estrogen 
receptor mediated process. 
A parallel bimodal action observed in rat uterine and breast cancer cell growth 
experiments suggests that there is a common locus in the pathway of estradiol 
metabolism that is amenable to YCK interference. 
4.3.4 Attenuation of YCK on ornithine decarboxylase (ODC) induced by estrogen 
Ornithine decarboxylase (ODC) is inducible by estradiol in its target tissues to 
produce polyamines in preparation for cell proliferation. Thus ODC induction in 
uterus is a molecular marker of estradiol action. In an attempt to demonstrate the 
genomic estrogenic activity of YCK, concurrent measurements of ODC activity and 
uterine hypertrophy were made. While YCK could induce ODC activities as a weak 
estrogen, it was surprising to find that YCK could attenuate estradiol action. Co-
administration of YCK and EE2 elicited a response reaching only 50% of the activity 
inducible by EE2 alone at the same dose level (Table 1). 
This result first suggested that YCK could be an anti-estrogen，perhaps by 
competitive receptor binding. But several attempts to demonstrate a dose dependent 
inhibition of uterotrophic activity by YCK on a fixed dose of EE2, as shown with 
triphenylethylene-type of anti-estrogen (Murphy et al., 1991)，were unsuccessful. 
« 
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A change of experimental protocol by running several estradiol dose response 
curves with increasing concentrations of YCK revealed the attenuation phenomenon. 
This is particularly evident in whole body experiments, like anti-implantation and 
uterotrophic assays, where a fairly precise inflexion point is demonstrable. It indicated 
a transition from the stimulatory mode of YCK activity, when estrogen stimulation was 
minimal, to the inhibitory mode, when estrogen stimulation was maximal. Although 
this inflexion point was not demonstrated in ODC induction and MCF-7 cell growth, 
they had nevertheless confirmed that attenuation is an inherent property of YCK in the 
presence of an optimal concentration of estrogen. 
4.4 Deviation between YCK potency and RBA 
It had been discussed in previous publications that the anti-fertility action of 
YCK was mainly attributable to its estrogenicity. In the present study, this estrogenic 
action was found to be positively related to estrogen receptor binding. However, any 
attempt to rationalise the action mechanism of YCK in this perspective was 
complicated by the observation that its biological potency in all estrogen receptor 
mediated systems could not correlate quantitatively with its relative binding affinity to 
estrogen receptor. In whole body experiment, like rat uterotrophic assay, YCK has a 
fairly strong relative estrogenic potency at 4-8% of estradiol (Chan et al” 1991) but the 
relative binding affinity of YCK in the uterine estrogen receptor was only 1/300 
(0.3%). At the organ level, like mice vaginal cornification, YCK has only 0.003% of 
relative estrogenic potency but showed a relative binding affinity at 1/150 (0.6%) in 
mice vaginae or uterine estrogen receptor. In MCF-7 cell, it is shown to have a relative 




Based on these observations, the ratio of relative estrogenic potency to RBA is 
high in whole body experiment but low in cell culture system and in local action on 
vagina. When YCK was delivered orally, the relative potency was high (4-8% in 
uterotrophic and anti-implantation assays). It was low (0.1-1%) when YCK was 
delivered in situ (intravaginal administration and cell culture). This observation 
suggested that biotransformation in liver might increase the potency, i.e., an active 
intermediate/metabolite with enhanced binding affinity and potency. If this is the case, 
it may not involve hydroxylation on the benzene ring as 6-OH-TCP was shown to be 
not more active than TCP. 
The discrepancy between estrogenic potency and RBA to estrogen receptor 
became more evident when comparing the anti-implantation activity of YCK with that 
of another phytoestrogen with higher RBA. Genistein has a RBA to estrogen receptor 
at 1/100 to 1/75. Following the protocol of routine anti-implantation assay, 12.5 
mg/kg genistein was not active whereas EE2 at 0.125 mg/kg was active. In the same 
experiment, it required a minimum effective dosage of 1.25 mg/kg for YCK. The 
result could be arranged as in the following table: 
Test sample effective relative RBA A/B 
dose (mg/kg) potency (A) W 
EE2 0.125 1 1 1 
YCK 1.25 1/10 1/150 15 
genistein > 12.5 < 1/100 1/75- < 1 
1/100* 
*: Shutt and Cox (1972) 
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It is quite obvious that higher RBA to estrogen receptor does not necessarily 
imply a higher potency in estrogenic action and vice versa. The anti-estrogenic 
potency of tamoxifen was greatly enhanced after 4-hydroxylation, so is its relative 
binding affinity (Murphy et al., 1991). In fact, this hydroxylated product was the most 
active of biotransformation products upon oral administration. YCK may behave 
likewise. In this respect, hydroxylated derivatives of TCP, a diminished analogue of 
YCK was made and tested. TCP (Cheng et al., 1994) was a YCK analogue with a 
truncated structure but still showing anti-implantation activity. The synthetic route to 
get TCP permits the controlled hydroxylation on either indole moiety independently. 
This facilitates the differentiation of the functional role of individual indole ring after 
addition of the hydroxyl group with regard to receptor binding. Unfortunately, 6-OH-
TCP did not show enhanced estrogen receptor binding as well as biological potency. 
Probably, 6-hydroxylation of TCP was not equivalent to the active biotranformation 
product(s) so that synthesis of other hydroxylated derivatives is needed before we can 
write off the contribution from aromatic hydroxylation. 
In addition to searching the contribution from hydroxylation on the indole 
moiety of YCK, the nitrogen atom on each indole ring might also confer binding 
affinity to estrogen receptor or genomic activation. This was attested by the fact that 
N-substituted YCK analogues elicited no activity in anti-implantation assay, MCF-7 
cell growth as well as estrogen receptor binding. It was becoming clearer today that 
the nitrogen atom on indole ring was critical to genomic activation and estrogen 
receptor binding. The clinical choice of anti-estrogen, tamoxifen, holds its anti-
estrogenic action by its alkylaminoethyoxy side chain on the a ‘ ring (Wolf and Jordan, 
1991). Other experimental anti-estrogens, such as the 11-B (Claussner et al., 1992; the 
RU series), 7a-substituted (Wakeling and Bowler, 1987; the ICI series) alkylamido-
estradiols and the 1 -aminoalky 1-2-phenylindole (von Angerrer et al., 1990) have clearly 
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confirmed the role of aminoalkyl side chain on anti-estrogenicity and estrogen receptor 
binding. Minute structural change of the alkyl substituents of the terminal amino 
group of 2-phenyl-indole series of anti-estrogens sufficed to render them inactive (von 
Angerrer et al., 1990). All these aminoalkyl side chain containing anti-estrogens are 
characterised by high RBA and the virtual absence of estrogenic activity. It is 
attractive to consider that if the ‘free，indole in YCK will act likewise. The nitrogen 
atom on the tetracyclic ring might be used to stabilise estrogen receptor binding but it 
is the nitrogen atom of the ‘‘free，，indole that confers anti-estrogenicity. In this regard, 
N-substituted YCK analogues must be re-tested for their anti-estrogenic activities. The 
‘free，indole moiety might provide too much free play as the steric hindrance reduced 
by a 2'-methyl group enhanced activity (Scheme. 3). Accordingly, the synthesis of 
YCK analogues with N-substitution on the ‘fixed，indole would be logically the next 
move in further structure-activity relationship study. Actually, synthesis of this kind of 
analogues is under way. 
4.5 Estrogen inhibition action of YCK via non receptor binding mechanism 
An estrogen antagonist either functions by occupying the estrogen receptor 
without activation; i.e., as a pure anti-estrogen, (e.g., ICI 164,384), or the occupancy 
causes receptor incompatibility with genomic activation, giving rise to partial 
agonistic/antagonistic action such as the triphenylethylene group of anti-estrogen, 
represented by TAM. YCK does not fall into either case. It was a non-competitive 
inhibtor in in vivo experiment (anti-implantation and uterotrophic assays) though it 
shows competitive displacement in estrogen receptor binding in vitro. It has low 
relative binding affinity and the degree of .estrogen receptor binding did not correlate 
with the potence of its biological action. Unlike TAM, it cannot bind competitively to 
the putative AEBS. It has attenuating effect on all organismic levels when estrogen 
level was high but it could also elicit weak estrogenicity at the same time when 
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Scheme 3 Bis-norr-YCK and its analogues (K.F. Cheng, personal communication). 
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estradiol level was low. It is therefore tempting to speculate that YCK may be anti-
estrogenic per se by acting on a pharmacological locus outside the receptor binding 
and genomic activation pathway. 
The starting material for the biomimetic synthesis of YCK is indole-3-
aldehyde, which is a close congenor of indole-3-carbinol (DC). The fact that 
3，3，diindolylmethane，an acid condensation product of I3C，which might share 
structural resemblance with indole-3-carboxyaldehyde derived YCK-like products, 
induced estradiol-2-hydroxylase, thus affording a protective effect in breast cancer 
development has led to many penetrating and exquisite research undertakings 
(Fishman et al., 1980; Bradfield and Bjeldanes, 1987; Michnovicz and Bradlow, 1990). 
The relevance of these comparisons to the present study would become significant if 
YCK indeed promotes estradiol-2-hydroxylase, thus attenuating or even depleting the 
endogenous estrogen pool by 2/16a-hydroxylation pathway of estrogen metabolism 
without going through estrogen receptor binding. Since YCK provided a limited 
degree of estrogenicity through estrogen receptor binding, the attenuation phenomenon 
was accompanied with a basal level of estrogenicity, but involving a different action 
mechanism. 
Since YCK is also an acid condensation product, it is therefore encouraging to 
note that oral administration of MBDI, the immediate precusor of YCK biomimetic 
synthesis, stimulated estradiol-2-hydroxylase and EROD in rat liver. EROD is an 
indicator of cytochrome P450 monoxygenases induction, including estradiol-2-
hydroxylase (Lubet et al., 1990; Baldwin and Leblanc, 1992). 
The ensemble of these results revealed a dichotomy of indole function. Whereas 
the to-indole in yuehchukene was estrogenic (uterotrophic and induction of ornithine 
. ‘ 
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decarboxylase), 3-substituted indoles were anti-estrogenic by inducing enzyme activities 
that could terminate estrogen action through 2-hydroxylation. 
The dichotomy of results could be graphically presented as follow: 
Uterus Liver 
Test compounds uterine wt. ornithine estradiol-2- ethoxyresorufin 
decarboxylase hydroxylase o-deethylase 
Yuehchukene ++ + _ 
methylbutadienyl-
indole 
- + / - + + 
indole-3-carbinol 
acid condensation 
- +/- ++ + 
product — 
As far as induction of enzyme activity is concerned, MBDI was much more 
active than YCK. As YCK is only one among many acid condensation products of 
MBDI, it is possible that some other more potent acid condensation products might 
exist. This casts doubts on possible YCK retro-degradation products similar to its 
precursor or that MBDI was metabolised to active intermediates resembling YCK in 
the liver. Furthermore, it was also obvious to the fact that there is dose dependence of 
MBDI but on a much elevated dose level implied that the active ingredient is a minor 
component of MBDI biotransformationn. This argument is supported by the fact that 
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3,3‘-diindolymethane is not the most potent inducer in enzyme induction. The most 
potent one is indole-[2,3-b]-carbazole, which is postulated to act via high affinity 
binding to aryl hydrocarbon (Ah) receptor due to structural resemblance to 2，3，7，8-
tetrachlorodibenzo-/7-dioxin (TCDD) (Bjeldanes et al., 1991). There are possibly other 
by-products or metabolites similar to 2-(indol-3-ylmethyl)-3,3'-diindolyImethane, 3.3'-
diindolymethane and indolo[3,2-b]carbazole that are more suitable structurally for Ah 
receptor binding (Jellinck et al., 1993). If this is the case, the total acid reaction 
mixture of MBDI after removing YCK must be re-examined in the light of anit-
estrognic activity. In fact, preliminary results showed that all the 3 non-overlapping 
fractions from MBDI acid condensation gave significant increase in enzyme activity. 
Among them, the further purified crude-YCK pool became the most active one on the 
same weight basis. This observation suggests that a minor component which is very 
close to YCK in structure is a more potent stimulator of estradiol-2-hydroxylase. 
4.6 Protein kinase C/calmodulin-dependent phosphodiesterase inhibitor 
It has been reported that the non-steroid anti-estrogen, TAM is an inhibitor of 
c a lmodu l i n -mediated phosphodiesterase as well as PKC. This is known as the 
alternative mechanism (other than the estrogen receptor binding) for TAM and these 
activities were observed at micromolar concentration range of TAM. Protein kinase C 
and calmodulin are thought to be involved in the control of cell proliferation and TAM 
blockade leading to cell cycle stopage at G1 phase (Sutherland et al., 1983; de Launoit 
et al., 1991). Since such effect appears to occur primarily in estrogen responsive cells, 
therefore it may somehow link to estrogen sensitivity. Accordingly, these 2 inhibitory 
effects of TAM and YCK might help to explain the non-specific cytotoxic activity 
(larger than 1 \xM) in the estrogen dependent MCF-7 cell line. But in the estrogen 
independent cell line, MDA-MB-231, similar cytotoxic activity was also observed at 
micromolar range. Preliminary attempts to look for any change in protein 
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• phosphorylation pattern caused by YCK and TAM did not yield any positive result. 
The autoradiography of phosphorylated protein in polyacrylamide gel failed to show 
any distinct difference in phosphorylation pattern when compared to vehicle control 
and TAM The cytotoxic action mechanism of YCK on these human breast cancer cell 
may not involve an interference of signal transduction. 
It is still unknown whether YCK will act similarly as TAM on the cell 
membrane. This may require further experiments in the future by comparing the 
phosphorylation pattern of estrogen and anti-estrogen. As mentioned above, some 
active metabolites or some kind of biotransformation product might enable YCK to 
manifest the observed mixed agonist/antagonist function in estrogen sensitive tissue, 
e.g., the uteri. In fact, the estrogenic/anti-estrogenic action of YCK cannot be fully 
explained by results of in vitro studies (estrogen receptor binding and cell culture 
system) that might be different from the final output which requires feedback control 
and multiple regulatory sites. In the present studies, protein kinase C and 
phosphodiesterase inhibition only revealed another facet of the multiple functions 
associated with the ^w-indole molecular design of YCK. The close resemblance 
between YCK and K252C, a potent protein kinase C and phosphodiesterase inhibitor 
isolated from fungus Nocardiopsis sp. K-290 is worth knowing. Besides, when 
comparing the estrogen receptor binding affinity, IC50, cytotoxic IC50 as well as the 
IC50 of phosphodiesterase/protein kinase C inhibitory action, both of them lie in the 
micromolar ranger, suggesting that the multifunction possessed by this molecular 
design would only reveal themselves with the dissociation of these functions in 
different active analogues yet to be made. 
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4.7 Progesterone receptor 
Since progesterone receptor was induced by the action of estrogen in estrogen 
primed cells and tissues, the demonstration of YCK on progesterone receptor binding 
give some insight into the genuine estrogenic action of YCK, and its possible 
mechanism in the attenuation of full estradiol response. However, preliminary 
attempts showed that YCK could not replace progesterone in luteotectomised pregnant 
rats. This means that the observed progesterone receptor competitive binding might 
not underlie the same attenuating phenomenon in both whole body and cell culture 
experiments. ' 
Considering its ability to displace competitively R5020 from progesterone 
receptor, i.e., YCK is a weak progesterone besides being an estrogen at the same time. 
Displacement curve, with respect to R5020 indicated a relative binding affinity of 
about 1/300. Considering the fact that R5020 is a specific, high affinity analogue more 
than progesterone, it is significant to note that the relative binding affinity of YCK 
with respect to progesterone receptor is at the same level as relative binding affinity of 
YCK to estrogen receptor. The possibility that YCK is capable of attenuating estrogen 
action through binding to progesterone receptor is worth investigating. 
It is well established that progesterone could be regarded as 
antagonist/modulator of estrogenic action if the target organ is estrogen primed 
beforehand. Hence, it is possible that YCK can first bind to estrogen receptor, causing 
an induction of progesterone receptor besides other estrogenic actions, such as the 
uterotrophic response observed in immature rat. Then, the continued administration of 
increasing amount of YCK can spill over to the progesterone receptor induced by the 
first phase of action. This scenario may positively correlate with observations in MCF-
7 cells where the bimodal growth response due to the administration of YCK resulted 
154 
in a reverse dose response curve. In case of co-administration of YCK and a high 
concentration of estradiol, the estradiol with much higher affinity totally saturates its 
estrogen receptor and hence the cytosolic estrogen receptor that are occupied by 
estradiol and are processed in the nucleus. The progesterone receptor induced by this 
initial action in target organ is then laid open to YCK when considering the much 
higher amount of YCK introduced to the cells which contain no or little progesterone. 
In final analysis, the estrogen action induced by estradiol is persistently suppressed by 
YCK through progesterone receptor binding. This might also account for the 
attenuation phenomenon in uterine growth and ODC induction. This was corroborated 
by the observation that the relative potency of YCK analogues on MCF-7 cell growth 
followed the order of their relative binding affinity to progesterone receptor. However, 
preliminary investigation regarding the progesterone effect of YCK in post-
implantation experiments i.e., support of gestation in leuteotectomised pregnant rats 
was inconclusive. Hence, even the progesterone property of YCK can be established 
in some other bioassay models, it is probably of minor importance in the attenuation of 
estrogen action discussed earlier. 
4.8 Aromatase Inhibitor? 
Phytoestrogens are natural compounds that occur in many plants and vegetables 
and they have estrogenic activity (Rose, 1992; Miksicek, 1993). Moreover, they 
possess mitogenic activity in MCF-7 breast cancer cells (Martin et al., 1978). YCK by 
virtue of its estrogenicity and plant origin cart no doubt be classified as phytoestrogens. 
Setchell et al. (1984) has proposed high level of equol (a kind of phytoestrogen) was 
excreted from human urine after consuming soy protein meals and this might yield 
protective effect against breast cancer. This benefit is possibly due to downregulating 
estrogen receptor by overwhelming the more potent estradiol in estrogen receptor 
binding (Martin et al., 1978; Folman and Pope, 1969). Epidemiological studies (Lee et 
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al.，1991; Goldin et al., 1982; Kagawa, 1978) which showed a lower risk in Japanese 
and Singapore women in breast cancer and this is associated to the consumption of 
large amount of soy products, a source of equol precursor (Setchell et al., 1984). But 
the evidence of tumour suppression done with equol type phytoestrogen is mainly 
circumstantial and lack of mechanistic proof. Comparison of YCK with Equol may 
not be conclusive at this stage. 
Another kind of estrogenic or anti-estrogenic plant product is formed by action 
of intestinal bacterial action on lignan. People eating whole grain cereals have lignans 
appearing in the urine at concentrations that increase in direct proportion to the amount 
of dietary fibre intake (Adlercreutz, et al., 1981; 1982). This has been attributed, at 
least in part, to the low rate of breast cancer in Finnish women eating whole grain as 
compared to American women who are not (Adlercreutz, 1990). Enterolactone and 
enterodiol are the major lignans from bacterial source observed in human urine. 
Investigators found that both bind in a relatively low affinity to estrogen receptors and 
exert weak estrogenic action (Adlercreutz, 1986). One interesting property of 
enterolactone is its capacity to inhibit placental aromatase. Aromatase inhibitor has 
long been an intense research target for the endocrine therapy of breast cancer (Santen 
et al., 1987). This leads to the postulation that the prptective effect of lignans on breast 
cancer might include attenuation of estrogen biosynthesis and bioactivity. Besides, the 
structure of enterolactone is similar to that of diethylstilbestrol, the synthetic 
nonsteroidal estrogen. 
A pilot study was initially launched to explore the possibility that YCK may be 
involved in steroid aromatase inhibition. Human placental microsome was chosen due 
to the presence of aromatase activity as well as the substantial amount of estradiol 2-
hydroxylase in the placenta (Fishman and Dixon, 1967). Preliminary results may 
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suffice to draw the conclusion that the cytotoxic effect of YCK on human breast cell 
culture and the attenuating phenomena observed in uterine hypertrophy and ODC 
induction as manifested by YCK probably do not stem from inhibition of steroid 
aromatase. Besides，oral administration of enterolactone failed to induce estradiol-2-
hydroxylase even at 5 mg/kg. 
4.9 Possible mechanism for the attenuation of estrogenic action by YCK 
. ‘ 
Among those multiple functions associated with the bis-indole molecular 
design of YCK, the most promising and noteworthy one with potentials of clinical 
significance is the activation of estradiol-2-hydroxylase in liver. If the mutually 
exclusive pathway of 2/16a-hydroxylation of estrogen can be selectively manipulated 
pharmacologically such as nicotine (Michnovicz et al” 1986) or cimetidine (Galbraith 
and Michnovicz, 1989) endogenous estrogen pool can be depleted or dampened. Oral 
administration of I3C, a well as MBDI will then become significant for potential breast 
cancer patients at high exposure to estradiol. After YCK binding to estrogen receptor, 
which are occupied by estradiol in the first place, it may spill over to Ah receptor 
binding and induce cytoplasmic P450 enzymes. This explains both the estrogenicity of 
YCK per se and the attenuating effect found on co-administration of YCK and 
estrogen. This is why the attenuation by YCK only becomes noticeable when there is a 
high level of estrogen. 
Moreover, the capability of binding competitively to progesterone receptor 
offers the possibility that YCK can act as progesterone agonist and counteract the 
action of estrogen. However, having binding affinity with both estrogen receptor and 
PR in target organs, bioavailability of YCK in this context becomes self-limiting 
except when p e r s i s t e n t administration of high dose of YCK occurs. -
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The PKC/PDE inhibitory action of YCK indicates that YCK can interfere with 
signal transduction pathway. Although contribution of this action on suppression of 
estrogenic function remains unclear in in vivo system, it may strengthen our 
understanding of the structure activity relationship of this bis-indole molecule. It 
provides ground for further structural modification. 
4.10 TCP series of YCK analogues 
Result from structure activity relationship of YCK analogues showed that YCK 
is a fairly conservative molecule. It would not allow any modification of the parent 
molecular structure without loss of biological activity，with the only exception that the 
saturation of the C9-C10 double bond resulted in an equipotent analogue in all models 
of bioassay. This prompts the idea of making a diminished YCK analogue with the 
elimination of the C9-C10 fragment. The synthetic approach to this diminished YCK, 
which is quite different from the condensation of 2 isoprenyl-indole precursors, 
afforded a selective hydroxylation of either one, or both, of the benzene ring at the C-3 
and C-T position of YCK. Since this position is equivalent to the C-3 position in 
estradiol in which the 3-hydroxy position is essential for estrogen receptor binding, it is 
speculated that 6-OH-TCP would manifest enhanced estrogen receptor binding and 
caused much improved biological activity. Whether the estrogenic mode or anti-
estrogenic mode of activity is affected remains to be seen. 
The ensemble of these results clearly indicated 6 hydroxylation, a position 
comparable to C-3 in YCK and estradiol could not improve the estrogenic potency of 
TCP analogues. Since 6-MeOH-TCP was similar to 6-OH-TCP in uterotrophic 
response and estrogen receptor, it is unlikely that conjugation at C-6-OH in TCP 
rendered it a futile addition. Methoxy-substitution of YCK at this position rendered it 
inactive. Although 3-hydroxylation is always considered as the primary binding site in 
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estradiol and 4 OH-TAM had dramatic increase in receptor binding and anti-estrogenic 
potence, the same criteria could not apply to YCK. It seems the cyclohcxenyl ring also 
contributes to receptor binding. It is corresponding to the D ring in estradiol and 6 ring 
in TAM. Hydroxylation in the benzene ring of TCP, a tricyclic structure, without the 
cyclohcxenyl ring could not improve binding or biological activity. This insight lends 
support to the hypothesis that full occupancy of the estrogen receptor induced folding, 
hence an active conformation for genomic binding. An anti-estrogen with an 
aminoethoxyl side chain hinders a complete folding. In this perspective, a 
hydroxylated YCK analogue with the tetracyclic skeleton (Cheng et al., 1994) but with 
N-substituted aminoalkyl side chain could possibly do away with the free indole 
moiety and at the same time increase the anti-estrogenic potency. This should be the 
next target in structure activity relationship. 
4.11 Future works 
The successful synthetic preparations of TCP (Cheng, 1994) enables the 
differential hydroxylation on either indole moiety independently. This has already 
made possible the study on the contribution of 6-hydroxylation on the “fixed，，indole 
moiety. Since, this analogue is not more active due to hydroxylation, it remains to be 
seen what is the effect of hydroxylation on the ‘free indole moiety. The N-substituted 
analogues of YCK will be retested for their anti-estrogenic activities. N-substitution 
with alkyamido side chain, on the ‘fixed‘ indole ring are to be made. Hopefully they 
will enhance both anti-estrogenic action vi^ genomic activation as well as relative 
binding affinity, like the 2-phenyl-indole anti-estrogen (von Angerrer et al., 1990) 
In addition to seeking the structural elements in intact YCK, the identification 
and purification of the active principle from MBDI acid condensation products in the 
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light of stimulating the estradiol-2-hydroxylase, EROD and Ah receptor binding 
affinity are most desirable. By monitoring the two approaches in their estrogenic/anti-
estrogenic activation via genomic activation and at pharmacological locus outside 
genomic activation, it may be possible to come up with a clearer picture about the 
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Appendix 2-1. Structure of compounds mentioned in this thesis (continued on the page 
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